**Current stage:** Gate H–K COMPLETE / PASS; Program A A1/A2A/A2B/A2C COMPLETE / PASS / CLOSED; bounded Program A pilot CLOSED; Program B master plan FROZEN; B0 = ACTIVE NEXT CHECKPOINT; PR #101 remains OPEN / DRAFT / UNMERGED unless separately changed.



---

## K4 Package 2 · INDUSTRIALS_CAPITAL_GOODS · Checkpoint B implementation — 22 September 2026

Checkpoint A is frozen COMPLETE / PASS.

Implemented:
- `industrialsK4bScoringMethodology.ts`;
- `industrialsK4bScoringMethodology.test.ts`;
- `industrialsK4bIsolationRegression.test.ts`;
- `docs/PortfolioAI_GATE_K_K4_2_INDUSTRIALS_CAPITAL_GOODS_CHECKPOINT_B.md`;
- canonical router extended for PROJECT_EPC / CAPITAL_EQUIPMENT_ELECTRICAL / DEFENCE_AEROSPACE;
- registry maps all three profiles to INDUSTRIALS_CAPITAL_GOODS in validation-pending state.

Deterministic scoring:
- ten dimensions totaling 100;
- mandatory evidence/history gates;
- no missing-input renormalization;
- distinct growth and cash-flow contracts for EPC, capital equipment and defence;
- symbol-independent methodology;
- unknown Industry → METHOD_NOT_AVAILABLE.

Incremental isolation/regression:
- PHARMA_V1 isolated;
- BANK_NBFC isolated;
- completed IT_TECH preserved;
- TORNTPHARM golden 75.1575 preserved;
- AUROPHARMA fail-closed golden preserved;
- universal Research workspace preserved.

Normal runtime scoring remains blocked while lifecycle = K4_FROZEN_PENDING. Promotion occurs only after owner-local Checkpoint B validation passes.

No provider calls, production mutation/migration, score/recommendation persistence, scheduler change, deployment, PR merge or trading action occurred.


---

## K4 Package 2 · Checkpoint B validation correction — 22 September 2026

Owner-local Checkpoint B validation initially reported 2 failed tests and 49 passed.

Both failures were stale expectations created by legitimate prior state transitions:

1. `industrialsK4aMethodologyContract.test.ts` still expected `CHECKPOINT_A_OWNER_APPROVAL_REQUIRED` after Checkpoint A had already been owner-approved and frozen to `CHECKPOINT_A_OWNER_APPROVED_LOCKED`.
2. `scoringProfileResolution.test.ts` still expected completed `IT_TECH` to fail closed to GENERAL. IT_TECH is now an implemented engine identity, so profile resolution correctly returns `IT_TECH` with `SECTOR_RULE`; its legacy ruleProfile remains GENERAL because specialised IT scoring is separately owned by the read-only K4B authority rather than the old GENERAL-derived database scaffold.

Only the tests were corrected. No runtime methodology, classification, score, recommendation, persistence, provider, scheduler, deployment or production behavior was changed.

Checkpoint B remains LOCAL VALIDATION PENDING until the corrected suite is rerun.


---

## K4 Package 2 · INDUSTRIALS_CAPITAL_GOODS FINAL CLOSURE — 22 September 2026

Owner-local corrected Checkpoint B suite and TypeScript passed completely.

Final state:
- Checkpoint A = COMPLETE / PASS / FROZEN;
- Checkpoint B = COMPLETE / PASS / CLOSED;
- registry lifecycle = IMPLEMENTED;
- supported subprofiles = PROJECT_EPC / CAPITAL_EQUIPMENT_ELECTRICAL / DEFENCE_AEROSPACE;
- ticker-specific methodology routing = NO;
- missing mandatory evidence = fail closed;
- working-capital/cash-conversion evidence remains mandatory;
- PHARMA_V1 / BANK_NBFC / IT_TECH isolation = PASS;
- golden controls = PASS;
- universal Research shell = PASS;
- score persistence = OFF;
- recommendation persistence = OFF.

**K4 Package 2 · INDUSTRIALS_CAPITAL_GOODS = COMPLETE / PASS / CLOSED.**

K4 Package 3 — AUTO_COMPONENTS Checkpoint A is now IN PROGRESS.


---

## K4 Package 3 · AUTO_COMPONENTS · Checkpoint A implementation — 22 September 2026

INDUSTRIALS_CAPITAL_GOODS is closed COMPLETE / PASS.

Added:
- `autoComponentsK4aMethodologyContract.ts`;
- `autoComponentsK4aMethodologyContract.test.ts`;
- `docs/PortfolioAI_GATE_K_K4_3_AUTO_COMPONENTS_CHECKPOINT_A.md`.

Proposed subprofiles:
1. AUTO_OEM — M&M and TVSMOTOR references;
2. AUTO_COMPONENTS — MOTHERSON and SONACOMS references.

Key methodology locks proposed:
- Industry selects methodology; Sector alone cannot;
- OEM and component economics remain separate;
- EV transition is exposure/risk/durability metadata, not an automatic third score;
- minimum 3 annual years / 8 quarters / 252 trading days;
- cash conversion and ROCE/ROIC are mandatory;
- capex-cycle context is mandatory;
- no cross-subprofile peer percentiles;
- unknown Industry → METHOD_NOT_AVAILABLE;
- numeric recommendation thresholds remain subprofile-owned and unset.

Runtime activation remains OFF pending owner-local Checkpoint A validation and approval.

No provider calls, production mutation/migration, score/recommendation persistence, scheduler change, deployment, PR merge or trading action occurred.


---

## K4 Package 3 · AUTO_COMPONENTS · Checkpoint A validation correction — 22 September 2026

Owner-local Checkpoint A validation initially reported 2 failed tests and 24 passed.

Both failures were stale registry expectations after the legitimate closure of earlier K4 packages:

1. the registry test still expected 9 packages in `K4_FROZEN_PENDING`; after IT_TECH and INDUSTRIALS_CAPITAL_GOODS are implemented, the correct count is 8;
2. the registry test still expected `PROJECT_EPC` to belong to a pending Industrials engine; INDUSTRIALS_CAPITAL_GOODS is now implemented, so the correct lifecycle is `IMPLEMENTED`.

Only regression expectations were updated. No AUTO methodology, routing, scoring, recommendation, production, persistence, provider, scheduler or deployment behavior changed.

AUTO_COMPONENTS Checkpoint A remains LOCAL VALIDATION PENDING until the corrected suite is rerun.


---

## K4 Package 3 · AUTO_COMPONENTS · Checkpoint A FINAL — 22 September 2026

Owner-local contract tests and TypeScript passed completely and the owner approved proceeding.

`AUTO_COMPONENTS_K4A_METHODOLOGY_V1` is now frozen with two subprofiles:
- AUTO_OEM;
- AUTO_COMPONENTS.

EV transition remains exposure/risk/durability metadata rather than a separate score.

Runtime activation remains OFF until Checkpoint B portability/isolation validation passes.

**AUTO_COMPONENTS Checkpoint A = COMPLETE / PASS / FROZEN.**

Checkpoint B is now IN PROGRESS.


---

## K4 Package 3 · AUTO_COMPONENTS · Checkpoint B implementation — 22 September 2026

Checkpoint A is frozen COMPLETE / PASS.

Implemented:
- `autoComponentsK4bScoringMethodology.ts`;
- `autoComponentsK4bScoringMethodology.test.ts`;
- `autoComponentsK4bIsolationRegression.test.ts`;
- `docs/PortfolioAI_GATE_K_K4_3_AUTO_COMPONENTS_CHECKPOINT_B.md`;
- canonical router extended for AUTO_OEM / AUTO_COMPONENTS coverage including tractors/farm equipment and tyres/rubber products;
- registry maps both profiles to AUTO_COMPONENTS in validation-pending state.

Deterministic scoring:
- ten dimensions totaling 100;
- mandatory evidence/history gates;
- no missing-input renormalization;
- distinct OEM vs component growth contracts;
- EV transition remains durability/risk metadata and never creates a second score;
- symbol-independent methodology;
- unknown Industry → METHOD_NOT_AVAILABLE.

Incremental isolation/regression:
- PHARMA_V1 isolated;
- BANK_NBFC isolated;
- completed IT_TECH preserved;
- completed INDUSTRIALS_CAPITAL_GOODS preserved;
- TORNTPHARM golden 75.1575 preserved;
- AUROPHARMA fail-closed golden preserved;
- universal Research workspace preserved.

Normal runtime scoring remains blocked while lifecycle = K4_FROZEN_PENDING. Promotion occurs only after owner-local Checkpoint B validation passes.

No provider calls, production mutation/migration, score/recommendation persistence, scheduler change, deployment, PR merge or trading action occurred.


---

## K4 Package 3 · AUTO_COMPONENTS · Checkpoint B validation correction — 22 September 2026

Owner-local Checkpoint B validation initially reported 1 failed test and 50 passed.

The single failure was a stale Checkpoint A expectation:
- `autoComponentsK4aMethodologyContract.test.ts` still expected `CHECKPOINT_A_OWNER_APPROVAL_REQUIRED`;
- the contract had already been owner-approved and frozen to `CHECKPOINT_A_OWNER_APPROVED_LOCKED`.

Only the regression expectation was updated. No AUTO routing, scoring methodology, recommendation behavior, persistence, provider, production, scheduler or deployment behavior changed.

AUTO_COMPONENTS Checkpoint B remains LOCAL VALIDATION PENDING until the corrected suite is rerun.


---

## K4 Package 3 · AUTO_COMPONENTS FINAL CLOSURE — 22 September 2026

Owner-local corrected Checkpoint B suite and TypeScript passed completely.

Final state:
- Checkpoint A = COMPLETE / PASS / FROZEN;
- Checkpoint B = COMPLETE / PASS / CLOSED;
- registry lifecycle = IMPLEMENTED;
- supported subprofiles = AUTO_OEM / AUTO_COMPONENTS;
- ticker-specific methodology routing = NO;
- missing mandatory evidence = fail closed;
- EV transition = durability/risk/exposure metadata only;
- PHARMA_V1 / BANK_NBFC / IT_TECH / INDUSTRIALS_CAPITAL_GOODS isolation = PASS;
- golden controls = PASS;
- universal Research shell = PASS;
- score persistence = OFF;
- recommendation persistence = OFF.

**K4 Package 3 · AUTO_COMPONENTS = COMPLETE / PASS / CLOSED.**

K4 Package 4 — CHEMICALS_V1 Checkpoint A is now IN PROGRESS.


---

## K4 Package 4 · CHEMICALS_V1 · Checkpoint A implementation — 22 September 2026

AUTO_COMPONENTS is closed COMPLETE / PASS.

Added:
- `chemicalsK4aMethodologyContract.ts`;
- `chemicalsK4aMethodologyContract.test.ts`;
- `docs/PortfolioAI_GATE_K_K4_4_CHEMICALS_CHECKPOINT_A.md`.

Proposed subprofiles:
1. SPECIALTY_CHEMICALS — PIIND / SRF references; VINATIORGA control;
2. AGRO_FERTILISER — PIIND / DEEPAKFERT references;
3. COMMODITY_PROCESS_CHEMICALS — SRF / DEEPAKFERT references.

Key methodology locks proposed:
- Industry selects methodology; Sector alone cannot;
- minimum 3 annual years / 8 quarters / 252 trading days;
- cycle-normalised growth, margin and ROCE interpretation;
- capacity/utilisation must be reconciled with return on capital;
- feedstock/global pricing context mandatory where material;
- no cross-subprofile peer percentiles;
- unknown Industry → METHOD_NOT_AVAILABLE;
- numeric recommendation thresholds remain subprofile-owned and unset.

Runtime activation remains OFF pending owner-local Checkpoint A validation and approval.

No provider calls, production mutation/migration, score/recommendation persistence, scheduler change, deployment, PR merge or trading action occurred.


---

## K4 Package 4 · CHEMICALS_V1 · Checkpoint A validation correction — 22 September 2026

Owner-local Checkpoint A validation initially reported 2 failed tests and 24 passed.

Both failures were stale registry lifecycle expectations after AUTO_COMPONENTS was legitimately promoted to IMPLEMENTED:
1. pending K4 package count was still hard-coded as 8, but the correct current count is 7;
2. AUTO_OEM was still expected to belong to a pending AUTO_COMPONENTS engine, while AUTO_COMPONENTS is now IMPLEMENTED.

To prevent the same avoidable failure after every subsequent K4 package, the registry lifecycle test was improved rather than merely changing 8 → 7:
- total registry entries must remain 12;
- excluding inherited PHARMA_V1 and BANK_NBFC, exactly 10 K4 packages must exist;
- each K4 package must be either IMPLEMENTED or K4_FROZEN_PENDING.

AUTO_OEM lifecycle expectation was updated to IMPLEMENTED.

No Chemicals methodology, routing, scoring, recommendation, persistence, provider, production, scheduler or deployment behavior changed.

CHEMICALS_V1 Checkpoint A remains LOCAL VALIDATION PENDING until the corrected suite is rerun.


---

## K4 Package 4 · CHEMICALS_V1 · Checkpoint A FINAL — 22 September 2026

Owner-local contract tests and TypeScript passed completely and the owner approved proceeding.

`CHEMICALS_V1_K4A_METHODOLOGY_V1` is now frozen with three subprofiles:
- SPECIALTY_CHEMICALS;
- AGRO_FERTILISER;
- COMMODITY_PROCESS_CHEMICALS.

Runtime activation remains OFF until Checkpoint B portability/isolation validation passes.

**CHEMICALS_V1 Checkpoint A = COMPLETE / PASS / FROZEN.**

Checkpoint B is now IN PROGRESS.


---

## K4 Package 4 · CHEMICALS_V1 · Checkpoint B implementation — 22 September 2026

Checkpoint A is frozen COMPLETE / PASS.

Implemented:
- `chemicalsK4bScoringMethodology.ts`;
- `chemicalsK4bScoringMethodology.test.ts`;
- `chemicalsK4bIsolationRegression.test.ts`;
- `docs/PortfolioAI_GATE_K_K4_4_CHEMICALS_CHECKPOINT_B.md`;
- canonical router extended for SPECIALTY_CHEMICALS / AGRO_FERTILISER / COMMODITY_PROCESS_CHEMICALS;
- registry maps all three profiles to CHEMICALS_V1 in validation-pending state.

Deterministic scoring:
- ten dimensions totaling 100;
- mandatory evidence/history gates;
- no missing-input renormalization;
- distinct growth contracts for specialty, agro/fertiliser and commodity/process chemicals;
- cycle normalization required;
- symbol-independent methodology;
- unknown Industry → METHOD_NOT_AVAILABLE.

Incremental isolation/regression:
- PHARMA_V1 isolated;
- BANK_NBFC isolated;
- completed IT_TECH preserved;
- completed INDUSTRIALS_CAPITAL_GOODS preserved;
- completed AUTO_COMPONENTS preserved;
- TORNTPHARM golden 75.1575 preserved;
- AUROPHARMA fail-closed golden preserved;
- universal Research workspace preserved.

Normal runtime scoring remains blocked while lifecycle = K4_FROZEN_PENDING. Promotion occurs only after owner-local Checkpoint B validation passes.

No provider calls, production mutation/migration, score/recommendation persistence, scheduler change, deployment, PR merge or trading action occurred.


---

## K4 Package 4 · CHEMICALS_V1 · Checkpoint B validation correction — 22 September 2026

Owner-local Checkpoint B validation initially reported 1 failed test and 51 passed.

The single failure was a stale Checkpoint A expectation:
- `chemicalsK4aMethodologyContract.test.ts` still expected `CHECKPOINT_A_OWNER_APPROVAL_REQUIRED`;
- the contract had already been owner-approved and frozen to `CHECKPOINT_A_OWNER_APPROVED_LOCKED`.

Only the regression expectation was updated. No Chemicals routing, scoring methodology, recommendation behavior, persistence, provider, production, scheduler or deployment behavior changed.

CHEMICALS_V1 Checkpoint B remains LOCAL VALIDATION PENDING until the corrected suite is rerun.


---

## K4 Package 4 · CHEMICALS_V1 FINAL CLOSURE — 22 September 2026

Owner-local corrected Checkpoint B suite and TypeScript passed completely.

Final state:
- Checkpoint A = COMPLETE / PASS / FROZEN;
- Checkpoint B = COMPLETE / PASS / CLOSED;
- registry lifecycle = IMPLEMENTED;
- supported subprofiles = SPECIALTY_CHEMICALS / AGRO_FERTILISER / COMMODITY_PROCESS_CHEMICALS;
- ticker-specific methodology routing = NO;
- missing mandatory evidence = fail closed;
- cycle normalization = mandatory;
- PHARMA_V1 / BANK_NBFC / prior K4 engine isolation = PASS;
- golden controls = PASS;
- universal Research shell = PASS;
- score persistence = OFF;
- recommendation persistence = OFF.

**K4 Package 4 · CHEMICALS_V1 = COMPLETE / PASS / CLOSED.**

K4 Package 5 — HEALTHCARE_SERVICES_V1 Checkpoint A is now IN PROGRESS.


---

## K4 Package 5 · HEALTHCARE_SERVICES_V1 · Checkpoint A implementation — 22 September 2026

CHEMICALS_V1 is closed COMPLETE / PASS.

Added:
- `healthcareServicesK4aMethodologyContract.ts`;
- `healthcareServicesK4aMethodologyContract.test.ts`;
- `docs/PortfolioAI_GATE_K_K4_5_HEALTHCARE_SERVICES_CHECKPOINT_A.md`.

Initial scope intentionally contains one subprofile:
- HOSPITAL_OPERATORS — MAXHEALTH / NH / MEDANTA / YATHARTH references.

Key methodology locks proposed:
- Industry selects methodology; Sector alone cannot;
- diagnostics are explicitly excluded from hospital scoring and must fail review pending separate methodology authority;
- minimum 3 annual years / 8 quarterly observations / 252 trading days;
- hospital operating evidence includes occupancy, ARPOB/equivalent and bed-ramp context where disclosed;
- bed additions must reconcile with ramp and ROCE;
- cash conversion must reconcile with capex/receivables;
- unknown/non-hospital Healthcare identity → METHOD_NOT_AVAILABLE / review;
- numeric recommendation thresholds remain subprofile-owned and unset.

Runtime activation remains OFF pending owner-local Checkpoint A validation and approval.

No provider calls, production mutation/migration, score/recommendation persistence, scheduler change, deployment, PR merge or trading action occurred.


---

## K4 Package 5 · HEALTHCARE_SERVICES_V1 · Checkpoint A validation correction — 22 September 2026

Owner-local Checkpoint A validation initially reported 1 failed test and 26 passed.

The single failure was a stale registry lifecycle expectation:
- `SPECIALTY_CHEMICALS` was still expected to belong to CHEMICALS_V1 with lifecycle `K4_FROZEN_PENDING`;
- CHEMICALS_V1 had already been closed and promoted to `IMPLEMENTED`.

Only the regression expectation was updated. No Healthcare Services methodology, routing, scoring, recommendation, persistence, provider, production, scheduler or deployment behavior changed.

HEALTHCARE_SERVICES_V1 Checkpoint A remains LOCAL VALIDATION PENDING until the corrected suite is rerun.


---

## K4 Package 5 · HEALTHCARE_SERVICES_V1 · Checkpoint A FINAL — 22 September 2026

Owner-local tests and TypeScript passed. The hospital-only initial methodology is frozen.

From this checkpoint onward, K4 regression tests must avoid stale lifecycle assumptions:
- completed engines are asserted as IMPLEMENTED;
- only the active package may be K4_FROZEN_PENDING;
- package-count invariants remain dynamic;
- no test may retain a pre-approval or pre-closure expected state after the state transition is committed.

**HEALTHCARE_SERVICES_V1 Checkpoint A = COMPLETE / PASS / FROZEN.**


---

## K4 Package 5 · HEALTHCARE_SERVICES_V1 · Checkpoint B implementation — 22 September 2026

Checkpoint A is frozen COMPLETE / PASS.

Implemented:
- `healthcareServicesK4bScoringMethodology.ts`;
- `healthcareServicesK4bScoringMethodology.test.ts`;
- `healthcareServicesK4bIsolationRegression.test.ts`;
- `docs/PortfolioAI_GATE_K_K4_5_HEALTHCARE_SERVICES_CHECKPOINT_B.md`;
- registry maps `HOSPITAL` to HEALTHCARE_SERVICES_V1 in validation-pending state;
- diagnostics remain deliberately unmapped from the hospital engine.

Deterministic scoring:
- ten dimensions totaling 100;
- hospital-specific operating durability evidence;
- no missing-input renormalization;
- diagnostics → REVIEW_REQUIRED / separate methodology required;
- symbol-independent methodology;
- score/recommendation persistence remain OFF.

Regression policy improvement:
- the current package test is lifecycle-stable and valid both before and after promotion;
- no stale pre-approval/pre-closure expectation is intentionally carried into this B suite;
- completed packages are asserted only in their durable IMPLEMENTED state.

Incremental isolation/regression:
- PHARMA_V1 isolated;
- BANK_NBFC isolated;
- IT_TECH / INDUSTRIALS_CAPITAL_GOODS / AUTO_COMPONENTS / CHEMICALS_V1 preserved;
- TORNTPHARM golden 75.1575 preserved;
- AUROPHARMA fail-closed golden preserved;
- universal Research workspace preserved.

Normal runtime scoring remains blocked while lifecycle = K4_FROZEN_PENDING. Promotion occurs only after owner-local Checkpoint B validation passes.

No provider calls, production mutation/migration, score/recommendation persistence, scheduler change, deployment, PR merge or trading action occurred.


---

## K4 Package 5 · HEALTHCARE_SERVICES_V1 · Checkpoint B precision correction — 22 September 2026

Owner-local Checkpoint B validation initially reported 1 failed test and 52 passed.

The failure was not a stale lifecycle expectation and not a methodology error. JavaScript floating-point arithmetic produced `73.99999999999999` for a weighted score that is mathematically 74.

Correction:
- deterministic K4B scorers now apply a stable output rounding step with `Number(value.toFixed(6))` to the final weighted overall score;
- the same stable precision rule was applied proactively to IT_TECH, INDUSTRIALS_CAPITAL_GOODS, AUTO_COMPONENTS and CHEMICALS_V1 scorers to prevent the same numerical artifact from recurring.

No weights, dimensions, methodology, evidence rules, routing, recommendation logic, persistence, provider behavior, production behavior, scheduler or deployment behavior changed.

HEALTHCARE_SERVICES_V1 Checkpoint B remains LOCAL VALIDATION PENDING until the corrected suite is rerun.


---

## K4 Package 5 · HEALTHCARE_SERVICES_V1 FINAL CLOSURE — 22 September 2026

Owner-local corrected Checkpoint B suite and TypeScript passed completely.

Final state:
- Checkpoint A = COMPLETE / PASS / FROZEN;
- Checkpoint B = COMPLETE / PASS / CLOSED;
- registry lifecycle = IMPLEMENTED;
- supported authority = HOSPITAL;
- diagnostics remain deliberately outside hospital scoring;
- ticker-specific methodology routing = NO;
- missing mandatory evidence = fail closed;
- PHARMA_V1 / BANK_NBFC / prior K4 engine isolation = PASS;
- golden controls = PASS;
- universal Research shell = PASS;
- stable weighted-score precision = 6 decimals;
- score persistence = OFF;
- recommendation persistence = OFF.

**K4 Package 5 · HEALTHCARE_SERVICES_V1 = COMPLETE / PASS / CLOSED.**

K4 Package 6 — FIN_SERVICES_NON_LENDER Checkpoint A is now IN PROGRESS.


---

## K4 Package 6 · FIN_SERVICES_NON_LENDER · Checkpoint A implementation — 22 September 2026

HEALTHCARE_SERVICES_V1 is closed COMPLETE / PASS.

Added:
- `finServicesNonLenderK4aMethodologyContract.ts`;
- `finServicesNonLenderK4aMethodologyContract.test.ts`;
- `docs/PortfolioAI_GATE_K_K4_6_FIN_SERVICES_NON_LENDER_CHECKPOINT_A.md`.

Proposed mandatory subprofiles:
1. CAPITAL_MARKETS_AMC — NAM-INDIA / HDFCAMC / ANGELONE / CAMS;
2. INSURANCE — STARHEALTH;
3. FINTECH_PLATFORM — PAYTM / POLICYBZR.

Key methodology locks proposed:
- non-lender Financial Services must not inherit BANK_NBFC lender metrics or thresholds;
- no NPA / CET1 / deposit-growth methodology leakage;
- Nifty Bank is not a benchmark authority for this package;
- subprofile-specific evidence and valuation are mandatory;
- insurance claims/reserving evidence cannot be replaced by generic margins;
- fintech growth cannot override cash burn/unit economics;
- cross-subprofile peer percentiles prohibited;
- unknown Industry → METHOD_NOT_AVAILABLE;
- numeric recommendation thresholds remain subprofile-owned and unset.

No-stale regression policy remains active for this package and subsequent K4 packages.

Runtime activation remains OFF pending owner-local Checkpoint A validation and approval.

No provider calls, production mutation/migration, score/recommendation persistence, scheduler change, deployment, PR merge or trading action occurred.


---

## K4 Package 6 · FIN_SERVICES_NON_LENDER · Checkpoint A FINAL — 22 September 2026

Owner-local tests and TypeScript passed. The three-subprofile non-lender Financial Services methodology is frozen.

Frozen subprofiles:
- CAPITAL_MARKETS_AMC;
- INSURANCE;
- FINTECH_PLATFORM.

Hard separation from BANK_NBFC remains mandatory.

**FIN_SERVICES_NON_LENDER Checkpoint A = COMPLETE / PASS / FROZEN.**

Checkpoint B is now IN PROGRESS.


---

## K4 Package 6 · FIN_SERVICES_NON_LENDER · Checkpoint B implementation — 22 September 2026

Checkpoint A is frozen COMPLETE / PASS.

Implemented:
- `finServicesNonLenderK4bScoringMethodology.ts`;
- `finServicesNonLenderK4bScoringMethodology.test.ts`;
- `finServicesNonLenderK4bIsolationRegression.test.ts`;
- `docs/PortfolioAI_GATE_K_K4_6_FIN_SERVICES_NON_LENDER_CHECKPOINT_B.md`;
- canonical router now uses CAPITAL_MARKETS_AMC / INSURANCE / FINTECH_PLATFORM;
- NBFC_LENDING remains separate under BANK_NBFC;
- registry maps all three non-lender profiles to FIN_SERVICES_NON_LENDER in validation-pending state.

Deterministic scoring:
- ten dimensions totaling 100;
- six-decimal stable weighted output;
- subprofile-specific evidence contracts;
- no missing-input renormalization;
- no lender-metric inheritance;
- symbol-independent methodology;
- unknown/lender Industry → METHOD_NOT_AVAILABLE for this engine.

Regression policy:
- Checkpoint A test was proactively aligned before B validation;
- current-package isolation is lifecycle-stable before/after promotion;
- completed engines are asserted only as IMPLEMENTED;
- no hard-coded shrinking pending-package count.

Incremental controls:
- PHARMA_V1 and BANK_NBFC isolated;
- K4 Packages 1–5 preserved;
- TORNTPHARM golden 75.1575 preserved;
- AUROPHARMA fail-closed golden preserved;
- universal Research workspace preserved.

Normal runtime scoring remains blocked while lifecycle = K4_FROZEN_PENDING. Promotion occurs only after owner-local Checkpoint B validation passes.

No provider calls, production mutation/migration, score/recommendation persistence, scheduler change, deployment, PR merge or trading action occurred.


---

## K4 Package 6 · FIN_SERVICES_NON_LENDER · Checkpoint B routing regression correction — 22 September 2026

Owner-local Checkpoint B validation initially reported 1 failed test and 53 passed.

The failure was a legacy profile-code expectation in `researchProfileRouting.test.ts`:
- old expected `CAPITAL_MARKET_FINANCIAL` while the frozen Package 6 profile is `CAPITAL_MARKETS_AMC`;
- old expected `DIGITAL_PLATFORM` while the frozen Package 6 profile is `FINTECH_PLATFORM`.

Only the regression expectations were updated to the frozen K4 profile identities. No routing logic, scoring methodology, lender separation, recommendation behavior, persistence, provider, production, scheduler or deployment behavior changed.

FIN_SERVICES_NON_LENDER Checkpoint B remains LOCAL VALIDATION PENDING until the corrected suite is rerun.


---

## K4 Package 6 · FIN_SERVICES_NON_LENDER FINAL CLOSURE — 22 September 2026

Owner-local corrected Checkpoint B suite and TypeScript passed completely.

Final state:
- Checkpoint A = COMPLETE / PASS / FROZEN;
- Checkpoint B = COMPLETE / PASS / CLOSED;
- registry lifecycle = IMPLEMENTED;
- supported subprofiles = CAPITAL_MARKETS_AMC / INSURANCE / FINTECH_PLATFORM;
- lender methodology inheritance = prohibited;
- NBFC_LENDING remains under BANK_NBFC;
- symbol-specific methodology routing = NO;
- missing mandatory evidence = fail closed;
- six-decimal stable weighted score precision retained;
- golden controls = PASS;
- universal Research shell = PASS;
- score persistence = OFF;
- recommendation persistence = OFF.

**K4 Package 6 · FIN_SERVICES_NON_LENDER = COMPLETE / PASS / CLOSED.**

K4 Package 7 — METALS_COMMODITIES Checkpoint A is now IN PROGRESS.


---

## K4 Package 7 · METALS_COMMODITIES · Checkpoint A implementation — 22 September 2026

FIN_SERVICES_NON_LENDER is closed COMPLETE / PASS.

Added:
- `metalsCommoditiesK4aMethodologyContract.ts`;
- `metalsCommoditiesK4aMethodologyContract.test.ts`;
- `docs/PortfolioAI_GATE_K_K4_7_METALS_COMMODITIES_CHECKPOINT_A.md`.

K1 open question resolved:
- METALS_COMMODITIES requires two methodology curves:
  1. STEEL_FERROUS — JINDALSTEL reference;
  2. NON_FERROUS_DIVERSIFIED_METALS — HINDALCO / HINDZINC references.

Key locks proposed:
- commodity exposure metadata mandatory;
- minimum 5 annual years / 12 quarters / 252 trading days;
- through-cycle normalization mandatory;
- cost curve/input integration context mandatory;
- leverage assessed at mid-cycle;
- spot P/E cannot be the sole valuation anchor;
- no cross-subprofile peer percentiles;
- unknown Industry → METHOD_NOT_AVAILABLE;
- recommendation thresholds remain subprofile-owned and unset.

No-stale regression policy remains active.

Runtime activation remains OFF pending owner-local Checkpoint A validation and approval.

No provider calls, production mutation/migration, score/recommendation persistence, scheduler change, deployment, PR merge or trading action occurred.


---

## K4 Package 7 · METALS_COMMODITIES · Checkpoint A FINAL — 22 September 2026

Owner-local tests and TypeScript passed completely.

`METALS_COMMODITIES_K4A_METHODOLOGY_V1` is frozen with:
- STEEL_FERROUS;
- NON_FERROUS_DIVERSIFIED_METALS.

**METALS_COMMODITIES Checkpoint A = COMPLETE / PASS / FROZEN.**

Checkpoint B is now IN PROGRESS.


---

## K4 Package 7 · METALS_COMMODITIES · Checkpoint B implementation — 22 September 2026

Checkpoint A is frozen COMPLETE / PASS.

Implemented:
- `metalsCommoditiesK4bScoringMethodology.ts`;
- `metalsCommoditiesK4bScoringMethodology.test.ts`;
- `metalsCommoditiesK4bIsolationRegression.test.ts`;
- `docs/PortfolioAI_GATE_K_K4_7_METALS_COMMODITIES_CHECKPOINT_B.md`;
- canonical router extended for STEEL_FERROUS / NON_FERROUS_DIVERSIFIED_METALS;
- registry maps both profiles to METALS_COMMODITIES in validation-pending state.

Deterministic scoring:
- ten dimensions totaling 100;
- six-decimal stable weighted output;
- mandatory commodity exposure metadata readiness gate;
- through-cycle normalization;
- mid-cycle leverage assessment;
- distinct steel vs non-ferrous growth contracts;
- spot P/E cannot be sole valuation anchor;
- symbol-independent methodology;
- missing mandatory evidence fails closed.

Regression policy:
- Checkpoint A test aligned before B validation;
- current-package isolation is lifecycle-stable;
- completed engines are asserted only as IMPLEMENTED;
- no hard-coded shrinking pending-package count.

Incremental controls:
- PHARMA_V1 / BANK_NBFC and K4 Packages 1–6 isolated/preserved;
- TORNTPHARM golden 75.1575 preserved;
- AUROPHARMA fail-closed golden preserved;
- universal Research workspace preserved.

Normal runtime scoring remains blocked while lifecycle = K4_FROZEN_PENDING. Promotion occurs only after owner-local Checkpoint B validation passes.

No provider calls, production mutation/migration, score/recommendation persistence, scheduler change, deployment, PR merge or trading action occurred.


---

## K4 Package 7 · METALS_COMMODITIES FINAL CLOSURE — 22 September 2026

Owner-local Checkpoint B suite and TypeScript passed completely.

Final state:
- Checkpoint A = COMPLETE / PASS / FROZEN;
- Checkpoint B = COMPLETE / PASS / CLOSED;
- registry lifecycle = IMPLEMENTED;
- supported subprofiles = STEEL_FERROUS / NON_FERROUS_DIVERSIFIED_METALS;
- commodity-exposure metadata = mandatory readiness gate;
- through-cycle normalization = mandatory;
- spot P/E as sole valuation anchor = prohibited;
- symbol-specific methodology routing = NO;
- missing mandatory evidence = fail closed;
- golden controls = PASS;
- universal Research shell = PASS;
- score persistence = OFF;
- recommendation persistence = OFF.

**K4 Package 7 · METALS_COMMODITIES = COMPLETE / PASS / CLOSED.**

K4 Package 8 — CONSUMER_FMCG Checkpoint A is now IN PROGRESS.


---

## K4 Package 8 · CONSUMER_FMCG · Checkpoint A implementation — 22 September 2026

METALS_COMMODITIES is closed COMPLETE / PASS.

Added:
- `consumerFmcgK4aMethodologyContract.ts`;
- `consumerFmcgK4aMethodologyContract.test.ts`;
- `docs/PortfolioAI_GATE_K_K4_8_CONSUMER_FMCG_CHECKPOINT_A.md`.

Initial profile:
- BRANDED_CONSUMER_FMCG.

Reference anchors:
- HINDUNILVR;
- VBL;
- LTFOODS;
- RADICO as alcohol-specific risk control.

Key methodology locks proposed:
- one initial branded/staples curve per K1;
- Industry selects methodology; Sector alone cannot;
- product/category metadata mandatory;
- alcohol excise/regulatory exposure is explicit risk metadata, not a separate universal score curve;
- minimum 3 annual years / 8 quarters / 252 trading days;
- volume/price/mix context where disclosed;
- raw-material inflation read with margin history;
- working capital and cash conversion are core evidence;
- unknown Industry → METHOD_NOT_AVAILABLE;
- recommendation thresholds remain profile-owned and unset.

No-stale regression policy remains active.

Runtime activation remains OFF pending owner-local Checkpoint A validation and approval.

No provider calls, production mutation/migration, score/recommendation persistence, scheduler change, deployment, PR merge or trading action occurred.


---

## K4 Package 8 · CONSUMER_FMCG · Checkpoint A FINAL — 22 September 2026

Owner-local tests and TypeScript passed completely.

`CONSUMER_FMCG_K4A_METHODOLOGY_V1` is frozen with one initial profile:
- BRANDED_CONSUMER_FMCG.

Product/category metadata remains mandatory. Alcohol remains an excise/regulatory risk variant rather than a separate universal score curve.

**CONSUMER_FMCG Checkpoint A = COMPLETE / PASS / FROZEN.**

Checkpoint B is now IN PROGRESS.


---

## K4 Package 8 · CONSUMER_FMCG · Checkpoint B implementation — 22 September 2026

Checkpoint A is frozen COMPLETE / PASS.

Implemented:
- `consumerFmcgK4bScoringMethodology.ts`;
- `consumerFmcgK4bScoringMethodology.test.ts`;
- `consumerFmcgK4bIsolationRegression.test.ts`;
- `docs/PortfolioAI_GATE_K_K4_8_CONSUMER_FMCG_CHECKPOINT_B.md`;
- canonical router extended for BRANDED_CONSUMER_FMCG;
- registry maps the profile to CONSUMER_FMCG in validation-pending state.

Deterministic scoring:
- ten dimensions totaling 100;
- six-decimal stable weighted output;
- mandatory PRODUCT_CATEGORY_METADATA readiness gate;
- one branded/staples scoring curve per K1;
- alcohol remains explicit excise/regulatory risk metadata, not a separate universal curve;
- symbol-independent methodology;
- missing mandatory evidence fails closed.

Regression policy:
- Checkpoint A test aligned before B validation;
- current-package isolation is lifecycle-stable;
- completed engines are asserted only as IMPLEMENTED;
- no hard-coded shrinking pending-package count.

Incremental controls:
- PHARMA_V1 / BANK_NBFC and K4 Packages 1–7 isolated/preserved;
- TORNTPHARM golden 75.1575 preserved;
- AUROPHARMA fail-closed golden preserved;
- universal Research workspace preserved.

Normal runtime scoring remains blocked while lifecycle = K4_FROZEN_PENDING. Promotion occurs only after owner-local Checkpoint B validation passes.

No provider calls, production mutation/migration, score/recommendation persistence, scheduler change, deployment, PR merge or trading action occurred.


---

## K4 Package 8 · CONSUMER_FMCG FINAL CLOSURE — 22 September 2026

Owner-local Checkpoint B suite and TypeScript passed completely.

Final state:
- Checkpoint A = COMPLETE / PASS / FROZEN;
- Checkpoint B = COMPLETE / PASS / CLOSED;
- registry lifecycle = IMPLEMENTED;
- supported profile = BRANDED_CONSUMER_FMCG;
- product/category metadata = mandatory readiness gate;
- alcohol = explicit excise/regulatory risk metadata, not a separate score curve;
- symbol-specific methodology routing = NO;
- missing mandatory evidence = fail closed;
- golden controls = PASS;
- universal Research shell = PASS;
- score persistence = OFF;
- recommendation persistence = OFF.

**K4 Package 8 · CONSUMER_FMCG = COMPLETE / PASS / CLOSED.**

K4 Package 9 — OIL_GAS_V1 Checkpoint A is now IN PROGRESS.


---

## K4 Package 9 · OIL_GAS_V1 · Checkpoint A implementation — 22 September 2026

CONSUMER_FMCG is closed COMPLETE / PASS.

Added:
- `oilGasK4aMethodologyContract.ts`;
- `oilGasK4aMethodologyContract.test.ts`;
- `docs/PortfolioAI_GATE_K_K4_9_OIL_GAS_CHECKPOINT_A.md`.

Mandatory K1 subprofiles preserved:
1. UPSTREAM_E_AND_P — ONGC;
2. MIDSTREAM_CITY_GAS — GAIL / MGL / IGL;
3. INTEGRATED_REFINING_PETCHEM — RELIANCE as mixed-business control, not sole authority.

Key methodology locks proposed:
- Industry selects methodology; Sector alone cannot;
- minimum 5 annual years / 12 quarterly cycle observations / 252 trading days;
- commodity and refining-cycle normalization mandatory;
- reserve/volume/throughput context required by subprofile;
- administered pricing/tax context required where material;
- energy-transition risk explicit;
- mixed-business controls cannot override pure-play economics;
- no cross-subprofile peer percentiles;
- unknown Industry → METHOD_NOT_AVAILABLE;
- recommendation thresholds remain subprofile-owned and unset.

No-stale regression policy remains active.

Runtime activation remains OFF pending owner-local Checkpoint A validation and approval.

No provider calls, production mutation/migration, score/recommendation persistence, scheduler change, deployment, PR merge or trading action occurred.


---

## K4 Package 9 · OIL_GAS_V1 · Checkpoint A FINAL — 22 September 2026

Owner-local tests and TypeScript passed completely.

`OIL_GAS_V1_K4A_METHODOLOGY_V1` is frozen with:
- UPSTREAM_E_AND_P;
- MIDSTREAM_CITY_GAS;
- INTEGRATED_REFINING_PETCHEM.

**OIL_GAS_V1 Checkpoint A = COMPLETE / PASS / FROZEN.**

Checkpoint B is now IN PROGRESS.


---

## K4 Package 9 · OIL_GAS_V1 · Checkpoint B implementation — 22 September 2026

Checkpoint A is frozen COMPLETE / PASS.

Implemented:
- `oilGasK4bScoringMethodology.ts`;
- `oilGasK4bScoringMethodology.test.ts`;
- `oilGasK4bIsolationRegression.test.ts`;
- `docs/PortfolioAI_GATE_K_K4_9_OIL_GAS_CHECKPOINT_B.md`;
- canonical router extended for UPSTREAM_E_AND_P / MIDSTREAM_CITY_GAS / INTEGRATED_REFINING_PETCHEM;
- registry maps all three profiles to OIL_GAS_V1 in validation-pending state.

Deterministic scoring:
- ten dimensions totaling 100;
- six-decimal stable weighted output;
- mandatory SUBPROFILE_OPERATING_CONTEXT readiness gate;
- through-cycle commodity/refining normalization;
- distinct subprofile growth contracts;
- RELIANCE remains a mixed-business control, not sole methodology authority;
- symbol-independent methodology;
- missing mandatory evidence fails closed.

Regression policy:
- Checkpoint A test aligned before B validation;
- current-package isolation is lifecycle-stable;
- completed engines are asserted only as IMPLEMENTED;
- no hard-coded shrinking pending-package count.

Incremental controls:
- PHARMA_V1 / BANK_NBFC and K4 Packages 1–8 isolated/preserved;
- TORNTPHARM golden 75.1575 preserved;
- AUROPHARMA fail-closed golden preserved;
- universal Research workspace preserved.

Normal runtime scoring remains blocked while lifecycle = K4_FROZEN_PENDING. Promotion occurs only after owner-local Checkpoint B validation passes.

No provider calls, production mutation/migration, score/recommendation persistence, scheduler change, deployment, PR merge or trading action occurred.


---

## K4 Package 9 · OIL_GAS_V1 FINAL CLOSURE — 22 September 2026

Owner-local Checkpoint B suite and TypeScript passed completely.

Final state:
- Checkpoint A = COMPLETE / PASS / FROZEN;
- Checkpoint B = COMPLETE / PASS / CLOSED;
- registry lifecycle = IMPLEMENTED;
- supported subprofiles = UPSTREAM_E_AND_P / MIDSTREAM_CITY_GAS / INTEGRATED_REFINING_PETCHEM;
- mandatory operating-context readiness gate retained;
- commodity/refining-cycle normalization mandatory;
- RELIANCE remains mixed-business control rather than sole authority;
- symbol-specific methodology routing = NO;
- missing mandatory evidence = fail closed;
- golden controls = PASS;
- universal Research shell = PASS;
- score persistence = OFF;
- recommendation persistence = OFF.

**K4 Package 9 · OIL_GAS_V1 = COMPLETE / PASS / CLOSED.**

K4 Package 10 — POWER_RENEWABLES_V1 Checkpoint A is now IN PROGRESS.


---

## K4 Package 10 · POWER_RENEWABLES_V1 · Checkpoint A implementation — 22 September 2026

OIL_GAS_V1 is closed COMPLETE / PASS.

Added:
- `powerRenewablesK4aMethodologyContract.ts`;
- `powerRenewablesK4aMethodologyContract.test.ts`;
- `docs/PortfolioAI_GATE_K_K4_10_POWER_RENEWABLES_CHECKPOINT_A.md`.

Mandatory K1 subprofiles preserved:
1. REGULATED_NETWORK — POWERGRID;
2. GENERATION_INTEGRATED_UTILITY — TATAPOWER / NHPC;
3. RENEWABLE_IPP — ACMESOLAR / KPIGREEN subject to identity review.

Key methodology locks proposed:
- Industry selects methodology; Sector alone cannot;
- minimum 5 annual years / 12 operating quarters / 252 trading days;
- tariff/regulatory context required where material;
- fuel/resource variability normalized for generation;
- PPA/offtaker/DISCOM quality required for contracted assets;
- leverage and refinancing sensitivity are core evidence;
- capacity growth cannot override cash-flow/execution weakness;
- transmission/grid-evacuation constraints are explicit risks;
- no cross-subprofile peer percentiles;
- unknown Industry → METHOD_NOT_AVAILABLE;
- recommendation thresholds remain subprofile-owned and unset.

No-stale regression policy remains active.

Runtime activation remains OFF pending owner-local Checkpoint A validation and approval.

No provider calls, production mutation/migration, score/recommendation persistence, scheduler change, deployment, PR merge or trading action occurred.


---

## K4 Package 10 · POWER_RENEWABLES_V1 · Checkpoint A FINAL — 22 September 2026

Owner-local tests and TypeScript passed completely.

`POWER_RENEWABLES_V1_K4A_METHODOLOGY_V1` is frozen with:
- REGULATED_NETWORK;
- GENERATION_INTEGRATED_UTILITY;
- RENEWABLE_IPP.

**POWER_RENEWABLES_V1 Checkpoint A = COMPLETE / PASS / FROZEN.**

Checkpoint B is now IN PROGRESS.


---

## K4 Package 10 · POWER_RENEWABLES_V1 · Checkpoint B implementation — 22 September 2026

Checkpoint A is frozen COMPLETE / PASS.

Implemented:
- `powerRenewablesK4bScoringMethodology.ts`;
- `powerRenewablesK4bScoringMethodology.test.ts`;
- `powerRenewablesK4bIsolationRegression.test.ts`;
- `docs/PortfolioAI_GATE_K_K4_10_POWER_RENEWABLES_CHECKPOINT_B.md`;
- canonical router extended for REGULATED_NETWORK / GENERATION_INTEGRATED_UTILITY / RENEWABLE_IPP;
- registry maps all three profiles to POWER_RENEWABLES_V1 in validation-pending state.

Deterministic scoring:
- ten dimensions totaling 100;
- six-decimal stable weighted output;
- mandatory TARIFF_PPA_OFFTAKER_GRID_CONTEXT readiness gate;
- distinct regulated-network / generation-utility / renewable-IPP growth contracts;
- leverage/refinancing is core evidence;
- project/grid/offtaker risk cannot be bypassed by capacity growth;
- symbol-independent methodology;
- missing mandatory evidence fails closed.

Regression policy:
- Checkpoint A test aligned before B validation;
- current-package isolation is lifecycle-stable;
- Packages 1–9 are asserted only as IMPLEMENTED;
- no hard-coded shrinking pending-package count.

Incremental controls:
- PHARMA_V1 / BANK_NBFC and K4 Packages 1–9 isolated/preserved;
- TORNTPHARM golden 75.1575 preserved;
- AUROPHARMA fail-closed golden preserved;
- universal Research workspace preserved.

Normal runtime scoring remains blocked while lifecycle = K4_FROZEN_PENDING. Promotion and formal K4 closure occur only after owner-local Checkpoint B validation passes.

No provider calls, production mutation/migration, score/recommendation persistence, scheduler change, deployment, PR merge or trading action occurred.


---

## K4 Package 10 · POWER_RENEWABLES_V1 FINAL CLOSURE — 22 September 2026

Owner-local final Checkpoint B suite and TypeScript passed completely.

Final state:
- Checkpoint A = COMPLETE / PASS / FROZEN;
- Checkpoint B = COMPLETE / PASS / CLOSED;
- registry lifecycle = IMPLEMENTED;
- supported subprofiles = REGULATED_NETWORK / GENERATION_INTEGRATED_UTILITY / RENEWABLE_IPP;
- tariff/PPA/offtaker/grid context = mandatory readiness gate;
- leverage/refinancing = core evidence;
- capacity growth cannot bypass cash-flow, execution, counterparty or grid-risk evidence;
- symbol-specific methodology routing = NO;
- missing mandatory evidence = fail closed;
- golden controls = PASS;
- universal Research shell = PASS;
- score persistence = OFF;
- recommendation persistence = OFF.

**K4 Package 10 · POWER_RENEWABLES_V1 = COMPLETE / PASS / CLOSED.**

---

## Gate K4 FINAL CLOSURE — 22 September 2026

All ten K4 packages are now COMPLETE / PASS / CLOSED:

1. IT_TECH
2. INDUSTRIALS_CAPITAL_GOODS
3. AUTO_COMPONENTS
4. CHEMICALS_V1
5. HEALTHCARE_SERVICES_V1
6. FIN_SERVICES_NON_LENDER
7. METALS_COMMODITIES
8. CONSUMER_FMCG
9. OIL_GAS_V1
10. POWER_RENEWABLES_V1

K4 global invariants preserved:
- Industry is the minimum micro-methodology selector;
- Sector is macro context only;
- no ticker-specific runtime methodology;
- no missing-input renormalization;
- no cross-subprofile leakage;
- deterministic read-only scoring;
- golden Pharma controls preserved;
- universal Research shell preserved;
- no score persistence;
- no recommendation persistence;
- no provider calls during K4 builds;
- no production mutation/migration;
- no scheduler change;
- no deployment;
- PR #101 remains OPEN / DRAFT / UNMERGED;
- no automatic trading.

**Gate K4 = COMPLETE / PASS / CLOSED.**

Next planned stage: **K5 — whole-portfolio coexistence and routing validation**.


---

## Gate K5 · Cross-Sector Isolation & Whole-Portfolio Validation implementation — 22 September 2026

Gate K4 is closed COMPLETE / PASS.

K5 implementation added:
- `k5CrossSectorValidation.ts`;
- `k5CurrentPortfolioRoutingSnapshot.ts` containing the frozen 238-equity K1 routing fixture;
- `k5CrossSectorIsolation.test.ts`;
- `k5WholePortfolioRouting.test.ts`;
- `k5RecommendationPortability.test.ts`;
- `docs/PortfolioAI_GATE_K_K5_CROSS_SECTOR_WHOLE_PORTFOLIO_VALIDATION.md`.

K5 validation design:
- registry-driven complete ordered pairwise engine isolation matrix;
- unique profile ownership;
- foreign methodology/benchmark/valuation/recommendation authority retrieval prohibited;
- all ten K4 engines required to remain IMPLEMENTED;
- every frozen current-portfolio row required to end in an explicit research architecture state;
- synthetic future-stock portability fixture for every currently SUPPORTED profile;
- unsupported sectors → METHODOLOGY_NOT_AVAILABLE;
- missing/conflicting classification → REVIEW_REQUIRED;
- no nearest-looking sector fallback;
- pending NBFC_LENDING and DIAGNOSTICS remain fail-closed;
- universal Research shell preserved;
- TORNTPHARM/AUROPHARMA golden controls preserved.

Recommendation portability study:
- universal semantics remain portable;
- numeric threshold portability = NOT_ESTABLISHED;
- pre-declared falsification tests encoded before any future portability claim;
- K5 introduces NO universal numeric recommendation thresholds;
- sector/profile-specific numeric policy still requires evidence and owner approval.

Safety unchanged:
- provider calls = 0;
- production mutation/migration = NO;
- score/recommendation persistence = OFF;
- position sizing = OFF;
- scheduler changes = NO;
- deployment = NO;
- PR merge = NO;
- automatic trading = NO.

**K5 status = IMPLEMENTED / LOCAL VALIDATION PENDING.**


---

## Gate K5 · Consolidated validation checkpoint — 22 September 2026

Current K5 candidate implementation was audited against the canonical Gate K plan before any additional methodology work.

Audit result:
- K5 is correctly implemented as a confirmation gate, not a methodology-building gate;
- 12 registered engine families imply 132 ordered pairwise isolation checks;
- methodology / benchmark / valuation / recommendation authority lookups are registry-owned and cross-engine lookup fails closed;
- every frozen K1 portfolio row is required to resolve to SUPPORTED_ENGINE / METHODOLOGY_NOT_AVAILABLE / REVIEW_REQUIRED / NOT_APPLICABLE;
- supported future-stock routing is classification-driven rather than ticker-driven;
- NBFC_LENDING and DIAGNOSTICS remain intentionally fail-closed pending dedicated authority;
- universal Research shell continuity is explicitly asserted;
- recommendation universal semantics are retained while numeric-threshold portability remains NOT_ESTABLISHED;
- pre-declared portability falsification tests are encoded before any future universal-threshold claim;
- no universal numeric recommendation threshold was introduced.

Consolidation improvement:
- added `scripts/k5-validate-cross-sector.sh`;
- this is now the single owner-local K5 closure command;
- it runs the full K5 isolation, routing, recommendation-portability, registry, profile-routing, scoring-resolution, K2 recommendation-safety, Research-workspace regression set, then TypeScript;
- no stale pre-approval / pre-promotion lifecycle assertion was added.

CI observation:
- initial K5 GitHub Architecture Guard run ended before any job step was created/executed, so it does not demonstrate a K5 test failure;
- separate Vercel status failed on a build-rate-limit condition;
- no runtime methodology or safety change was made in response.

Safety remains unchanged:
- provider calls = 0;
- production mutation/migration = NO;
- score persistence = OFF;
- recommendation persistence = OFF;
- position sizing = OFF;
- scheduler changes = NO;
- deployment = NO;
- PR merge = NO;
- automatic trading = NO.

**K5 status remains IMPLEMENTED / LOCAL VALIDATION PENDING.**

Required owner-local closure command:

```bash
git pull
bash scripts/k5-validate-cross-sector.sh
```


---

## Gate K5 · Chat rollover checkpoint — 22 September 2026

The owner explicitly instructed that K5 is now to be executed and supplied the canonical Gate K plan for continuity.

Canonical K5 scope reaffirmed:
- K5 is a confirmation gate, not a new methodology-building stage;
- complete registry-driven cross-sector isolation must be validated;
- every registered engine pair must remain isolated for methodology, benchmark, valuation, durability/recommendation authority and fallback behavior;
- future supported stocks must route by canonical classification without ticker-specific logic;
- unsupported sectors must fail safely to METHODOLOGY_NOT_AVAILABLE;
- conflicting or missing canonical classification must fail to REVIEW_REQUIRED rather than use a nearest-looking fallback;
- the universal Research workspace must remain shared across all engines;
- recommendation-policy portability must be evaluated using pre-declared falsification tests rather than assumed.

Current K5 repository state at chat rollover:
- K5 implementation is already present;
- consolidated K5 validation script exists at `scripts/k5-validate-cross-sector.sh`;
- frozen 238-equity K1 routing snapshot is part of K5 validation;
- complete cross-sector isolation/routing/recommendation-portability tests are present;
- universal numeric recommendation-threshold portability remains NOT_ESTABLISHED;
- no new methodology or threshold policy was introduced during the latest inspection;
- no provider refresh was authorized or performed.

Current owner-local closure command remains:

```bash
git pull
bash scripts/k5-validate-cross-sector.sh
```

K5 must not be marked COMPLETE / PASS / CLOSED until that consolidated owner-local validation passes and the result is recorded.

Permanent safety boundaries remain:
- no production mutation/migration;
- no score persistence;
- no recommendation persistence;
- no provider refresh unless explicitly approved;
- no scheduler changes;
- no deployment;
- no PR merge;
- no automatic trading.

PR #101 remains OPEN / DRAFT / UNMERGED.

**Current checkpoint: K5 IMPLEMENTED / LOCAL VALIDATION PENDING.**


---

## Gate K5 · First consolidated validation correction — 22 September 2026

Owner-local consolidated K5 validation result:
- 8 test files executed;
- 7 passed / 1 failed;
- 56 tests passed / 1 failed;
- the only failure was the synthetic future-stock portability case for `AUTO_OEM`.

Root cause:
- the K5 synthetic future-stock fixture used sector text `Automobile & Auto Components`;
- the frozen canonical routing identity is `Automobile and Auto Components`;
- the router correctly remained fail-closed because the synthetic fixture did not match the canonical classification key;
- the frozen 238-equity whole-portfolio routing test passed;
- the dedicated AUTO routing regression already passed;
- therefore this was a stale/non-canonical synthetic fixture, not a runtime methodology or routing defect.

Correction:
- updated only the two synthetic AUTO future-stock fixtures in `k5CrossSectorValidation.ts`;
- `AUTO_OEM` fixture now uses canonical sector `Automobile and Auto Components`;
- `AUTO_COMPONENTS` fixture now uses the same canonical sector identity;
- no router broadening was introduced;
- no methodology, benchmark, valuation, recommendation authority, lifecycle, persistence, provider, scheduler, deployment or production behavior changed.

K5 remains **IMPLEMENTED / LOCAL VALIDATION PENDING** until the consolidated suite is rerun.

Required rerun:

```bash
git pull
bash scripts/k5-validate-cross-sector.sh
```


---

## Gate K5 · FINAL CLOSURE — 22 September 2026

Owner-local consolidated K5 validation rerun passed completely after the non-canonical AUTO synthetic future-stock fixture was corrected.

Final K5 validation outcome:
- consolidated runner `scripts/k5-validate-cross-sector.sh` = PASS;
- cross-sector isolation = PASS;
- whole-portfolio routing = PASS;
- future-stock portability = PASS;
- recommendation portability study = PASS;
- registry regression = PASS;
- research profile routing = PASS;
- scoring profile resolution = PASS;
- K2 recommendation safety = PASS;
- universal Research workspace contract = PASS;
- TypeScript = PASS.

K5 exit conditions are satisfied:
- all 12 registered engine families coexist without methodology / benchmark / valuation / recommendation authority leakage;
- complete registry-driven ordered pairwise isolation passes;
- all ten K4 engines remain in durable IMPLEMENTED state;
- the frozen 238-equity K1 portfolio routing snapshot resolves only to explicit supported / unavailable / review / not-applicable architecture states;
- supported future stocks route by canonical classification without ticker-specific methodology;
- unsupported sectors fail safely to `METHODOLOGY_NOT_AVAILABLE`;
- missing/conflicting classification fails safely to `REVIEW_REQUIRED`;
- no nearest-looking fallback exists;
- the universal Research workspace contract remains intact;
- TORNTPHARM/AUROPHARMA golden controls remain stable;
- universal recommendation semantics are portable;
- universal numeric recommendation thresholds are NOT established as portable and must not be assumed;
- any future sector/profile-specific numeric recommendation authority still requires evidence and owner approval.

Permanent safety boundaries remain unchanged:
- no production mutation/migration;
- no score persistence;
- no recommendation persistence;
- no provider refresh unless explicitly approved;
- no position sizing activation;
- no scheduler changes;
- no deployment;
- no PR merge;
- no automatic trading.

PR #101 remains OPEN / DRAFT / UNMERGED.

**Gate K5 = COMPLETE / PASS / CLOSED.**

Next and final hard-capped Gate K stage: **K-FINAL — Portfolio Sector-Coverage Closure**.


---

## Gate K-FINAL · Portfolio Sector-Coverage Closure implementation — 22 September 2026

K5 is closed COMPLETE / PASS.

K-FINAL has been implemented as the final Gate K confirmation/closure package only. No new methodology or threshold policy was introduced.

Added:
- `src/features/research/kFinalPortfolioCoverage.ts`;
- `src/features/research/kFinalPortfolioCoverage.test.ts`;
- `scripts/k-final-validate-portfolio-coverage.sh`;
- `docs/PortfolioAI_GATE_K_FINAL_PORTFOLIO_SECTOR_COVERAGE_CLOSURE.md`.

Portfolio-wide closure matrix:
- generated from the frozen 238-equity K1/K5 routing snapshot;
- every holding resolves to exactly one architecture state:
  - ARCHITECTURE_READY;
  - METHODOLOGY_NOT_AVAILABLE;
  - REVIEW_REQUIRED;
  - NOT_APPLICABLE;
- supported holdings are deliberately marked score/recommendation EVIDENCE_DEPENDENT rather than falsely claiming evidence completeness;
- unsupported methodology fails closed to SCORE_NOT_COMPUTABLE / RECOMMENDATION_NOT_COMPUTABLE;
- unresolved/conflicting classification remains REVIEW_REQUIRED.

K-FINAL acceptance coverage includes:
- explicit architecture state for every frozen current holding;
- no cross-sector methodology leakage;
- future-stock portability;
- universal Research workspace continuity;
- fail-closed missing evidence;
- N/A distinct from missing;
- recommendation safety;
- complete registry-driven isolation;
- stable Pharma golden controls;
- unsupported-sector fail-safe behavior;
- score persistence OFF;
- recommendation persistence OFF;
- position sizing OFF;
- Gate K AI interpretation activation OFF;
- production mutation/migration OFF;
- deployment OFF;
- PR merge OFF;
- automatic trading OFF.

Consolidated owner-local validation command:

```bash
git pull
bash scripts/k-final-validate-portfolio-coverage.sh
```

The K-FINAL suite is lifecycle-stable and does not reintroduce stale pre-approval/pre-promotion expectations.

Permanent safety boundaries remain unchanged:
- no production mutation/migration;
- no score persistence;
- no recommendation persistence;
- no provider refresh unless explicitly approved;
- no position sizing activation;
- no AI interpretation activation under Gate K;
- no portfolio mutation;
- no scheduler changes;
- no deployment;
- no PR merge;
- no automatic trading.

**K-FINAL status = IMPLEMENTED / LOCAL VALIDATION PENDING.**

Gate K must not be marked COMPLETE / PASS until the consolidated K-FINAL command passes and the result is recorded.


---

## Gate K-FINAL · FINAL CLOSURE — 22 September 2026

Owner-local consolidated K-FINAL validation passed completely.

Final validation outcome:
- `scripts/k-final-validate-portfolio-coverage.sh` = PASS;
- K-FINAL portfolio coverage closure test = PASS;
- K5 cross-sector isolation = PASS;
- K5 whole-portfolio routing = PASS;
- K5 future-stock portability = PASS;
- K5 recommendation portability = PASS;
- K3 BANK_NBFC N/A semantics = PASS;
- K2 recommendation safety = PASS;
- Pharma read-only downstream safety = PASS;
- universal Research workspace regression = PASS;
- TypeScript = PASS.

Gate K final acceptance:
1. every frozen current holding has an explicit research-engine architecture state — PASS;
2. no stock silently inherits unrelated methodology — PASS;
3. supported sectors remain portable to future stocks — PASS;
4. all engines share the universal Research workspace — PASS;
5. missing mandatory evidence fails closed — PASS;
6. N/A remains distinct from missing — PASS;
7. recommendation safety semantics remain preserved — PASS;
8. cross-sector methodology isolation passes — PASS;
9. golden control outputs remain stable — PASS;
10. unsupported sectors safely report METHODOLOGY_NOT_AVAILABLE — PASS;
11. score persistence remains OFF — PASS;
12. recommendation persistence remains OFF — PASS;
13. position sizing remains OFF — PASS;
14. AI interpretation activation remains OFF under Gate K — PASS;
15. production mutation/migration remains OFF — PASS;
16. deployment remains OFF — PASS;
17. PR merge remains OFF — PASS;
18. automatic trading remains OFF — PASS.

Closure interpretation:
- portfolio classification + methodology architecture coverage is now complete/fail-closed;
- this does not claim all 238 holdings already have full evidence, computable scores or eligible recommendations;
- supported holdings may remain evidence-dependent;
- unsupported or unresolved holdings remain explicitly unavailable/review-required.

Permanent safety boundaries remain unchanged:
- no production mutation/migration;
- no provider refresh unless separately approved;
- no score persistence;
- no recommendation persistence;
- no position sizing activation;
- no AI interpretation activation under Gate K;
- no portfolio mutation;
- no scheduler changes;
- no deployment;
- no PR merge;
- no automatic trading.

**Gate K-FINAL = COMPLETE / PASS / CLOSED.**

**Gate K = COMPLETE / PASS.**

**Sector-specific research layer = PORTFOLIO COVERAGE COMPLETE.**

PR #101 remains OPEN / DRAFT / UNMERGED pending a separate explicit owner decision.


---

## Post-Gate-K architecture / roadmap audit — 23 September 2026

A detailed post-K reconciliation was completed against:
- PortfolioAI Master Blueprint;
- Research & Intelligence Architecture;
- Integration & Execution Plan;
- Requirements Register;
- living Development Status;
- R3/R4 routing plan;
- actual H→K implementation and closure records.

Audit document:
- `docs/PortfolioAI_POST_GATE_K_ARCHITECTURE_AND_ROADMAP_AUDIT.md`.

Primary conclusion:
- **no Gate L or Gate M is currently required or canonically defined**;
- creating L/M now would duplicate the existing R-roadmap and confuse methodology completion with evidence/execution breadth;
- Gate K has effectively superseded/completed the old **R4 generic sector/profile Research contract** objective.

What Gate K completed:
- portfolio-coverage/fail-closed research methodology architecture for the frozen Gate-K scope;
- 12 registered engine families;
- one universal Research workspace;
- industry/business-model methodology selection;
- future-stock portability;
- cross-sector isolation;
- unsupported/review-required fail-safe behavior;
- deterministic sector scoring methodology authorities;
- universal recommendation semantics, without assuming portable numeric thresholds.

What remains materially incomplete:
- R3 portfolio-wide fundamental/research evidence breadth;
- R5 portfolio-wide historical market evidence;
- R6 actual company-specific deterministic scoring execution;
- sector/profile numeric recommendation policy calibration where still pending;
- R7 recommendation + position-sizing rollout;
- R8 Core Health / Portfolio Fit / Risk / Exit engines;
- R9 Movement / meaningful-change detection;
- R10 Combined Action Center;
- R11 general scheduled maintenance;
- R12 optional AI Investment Committee.

Recommended consolidation:
- Program A = R3 + R5 Evidence Coverage;
- Program B = R6 + recommendation calibration + R7 Deterministic Portfolio Intelligence;
- Program C = R8 + R9 + R10 Portfolio Decision Engines;
- Program D = R11 + R12 Operations & Optional AI.

Immediate governance recommendation:
- do not add another large development chain to PR #101;
- PR #101 remains OPEN / DRAFT / UNMERGED and currently carries a very large accumulated scope;
- freeze the Gate-K handoff and decide PR #101 disposition before beginning Program A on a clean branch;
- production/provider execution remains separately approval-gated.

Living Development Status was reconciled to reflect:
- Gate K COMPLETE / PASS;
- old R4 objective superseded/completed by H→K;
- next substantive work = R3 + R5 breadth, not Gate L/M.

**Post-K roadmap status: AUDITED / RECONCILED / OWNER REVIEW PENDING.**


---

## Post-Gate-K canonical forthcoming action plan — 23 September 2026

Canonical plan created:
- `docs/PortfolioAI_POST_GATE_K_FORTHCOMING_ACTION_PLAN.md`.

This file is now the required roadmap reference before any new post-K Program begins.

Mandatory review rule:
- before Program A, B, C or D, review the forthcoming action plan;
- review this cumulative handoff;
- inspect the current branch/PR/runtime state;
- confirm prerequisites and stale assumptions;
- create a bounded Program-specific plan;
- obtain separate owner approval for any provider, production, persistence, scheduler, deployment or merge action.

Frozen post-K Program sequence:
- **Program A — Evidence Coverage = R3 + R5**;
- **Program B — Deterministic Portfolio Intelligence = R6 + recommendation calibration + R7**;
- **Program C — Portfolio Decision Engines = R8 + R9 + R10**;
- **Program D — Operations & Optional AI = R11 + R12**.

Gate L / Gate M:
- not currently required;
- not canonically defined;
- must not be created merely to rename the remaining R-roadmap;
- a new letter Gate is justified only by a genuinely new architecture problem.

Immediate prerequisite before Program A implementation:
- freeze Gate-K state;
- explicitly decide PR #101 disposition / branch strategy;
- start substantive Program A work on a clean post-K branch after that strategy is frozen.

Current statuses:
- Gate K = COMPLETE / PASS;
- Program A = NOT STARTED;
- Program B = NOT STARTED;
- Program C = NOT STARTED;
- Program D = NOT STARTED;
- PR #101 = OPEN / DRAFT / UNMERGED.

Permanent safety boundaries remain unchanged:
- no production mutation/migration without explicit approval;
- no provider execution without explicit approval;
- no broad Trendlyne cohort without explicit approval;
- no Angel One history backfill without explicit approval;
- no score/recommendation/sizing persistence without explicit approval;
- no scheduler activation;
- no portfolio mutation;
- no deployment;
- no PR merge;
- no automatic trading.

**Post-K forthcoming action plan = CREATED / CANONICAL / REQUIRED BEFORE EACH PROGRAM.**


---

## Post-K Reconciliation Checkpoint PKR-1 / PKR-1B — 23 September 2026

Purpose:
- reconcile the live Research scoring path and regression suite with the already-closed Gate-K fail-closed architecture before Program A begins;
- this checkpoint did not start Program A and did not change any financial scoring methodology.

Implementation commits:
- PKR-1: `412e3e36a6f435675d4293c4678c54d0b4acea8e`
- PKR-1B: `f22b4efc8607102c51abadd46c62f362fd837084`

### PKR-1 corrections

- TypeScript-safe optional access added to BANK/NBFC profile-authority regression tests;
- stale pre-closure K4 lifecycle tests updated to durable `IMPLEMENTED` expectations;
- unsupported/pending methodology no longer falls through to a scoreable `GENERAL` profile;
- missing/conflicting classification remains `REVIEW_REQUIRED`;
- unsupported/pending methodology becomes `METHODOLOGY_NOT_AVAILABLE`;
- fail-closed states short-circuit before scoring-model/evidence queries;
- Research UI shows explicit blocked state instead of a generic score preview;
- cached score snapshots cannot override a newer fail-closed state;
- `BANK_NBFC` family lifecycle remains intentionally `RECONCILIATION_REQUIRED` because BANK is supported while NBFC_LENDING remains `PENDING_METHODOLOGY`;
- no BANK benchmark/valuation/recommendation leakage into NBFC.

### PKR-1B final live-scoring reconciliation

A second issue was identified during ChatGPT diff audit: completed K4 engines still retained `ruleProfile = GENERAL`, which could have allowed legacy GENERAL numeric previews even though their Gate-K methodologies are sector-specific.

PKR-1B introduced an explicit separation:

```text
Methodology state
AVAILABLE
METHODOLOGY_NOT_AVAILABLE
REVIEW_REQUIRED

Score-execution state
AVAILABLE
PENDING_ADAPTER
BLOCKED
```

Final behavior:
- PHARMA_V1 and supported BANK scoring: methodology AVAILABLE + score execution AVAILABLE;
- completed K4 engines: methodology AVAILABLE + score execution PENDING_ADAPTER;
- completed K4 engines retain their sector engine identity but select no GENERAL rule profile;
- routed and reviewed K4 assignments cannot bypass the guard;
- unsupported methodology: METHODOLOGY_NOT_AVAILABLE + BLOCKED;
- missing/conflicting classification: REVIEW_REQUIRED + BLOCKED;
- NBFC_LENDING remains fail-closed;
- an explicit canonical GENERAL assignment may remain available where genuinely reviewed/authorized;
- Program B / R6 remains the owner of actual K4 live scorer-adapter activation.

This means Program A may expand evidence without causing a legacy GENERAL numeric score to appear increasingly authoritative for a K4 company.

### Validation

Owner/Codex local validation reported:
- PKR-1 focused K3/K4/scoring/UI suite: 201 tests PASS;
- PKR-1 K-FINAL consolidated suite: 39 tests PASS;
- PKR-1B focused scoring/UI/K3/K4 suite: 95 tests PASS;
- PKR-1B K-FINAL including K5 isolation: 39 tests PASS;
- TypeScript = PASS;
- architecture guard = PASS;
- production build = PASS;
- TORNTPHARM golden control = PASS;
- AUROPHARMA fail-closed control = PASS;
- cross-sector isolation = PASS;
- universal Research workspace = PASS.

Known non-blocking repository debt:
- full-repository lint still contains 77 pre-existing errors outside PKR-1/PKR-1B;
- existing Vite chunk-size warning remains.

Safety unchanged:
- no provider calls;
- no production mutation/migration;
- no score/recommendation/sizing persistence activation;
- no scheduler activation;
- no AI activation;
- no portfolio mutation;
- no deployment;
- no PR merge;
- no automatic trading.

**PKR-1 / PKR-1B = COMPLETE / PASS / CLOSED.**

Program A remains NOT STARTED.

Next governance step:
- freeze PR #101 at this post-K reconciled state;
- choose a clean post-K Program A working branch from commit `f22b4efc8607102c51abadd46c62f362fd837084`;
- do not merge PR #101 without a separate explicit owner decision;
- Program A A1 must be planned/frozen before Codex implementation.


---

## Program A launch · A1 plan freeze — 23 September 2026

Clean Program A branch created:
- `program-a-evidence-coverage`;
- branched from reconciled post-K tip `239c209005b549ce4c6eff260d284091afe972fc`;
- PR #101 remains untouched / OPEN / DRAFT / UNMERGED.

Canonical A1 plan:
- `docs/PortfolioAI_PROGRAM_A_A1_EVIDENCE_BASELINE_AND_EXECUTION_PLAN.md`.

A1 title:
- **Read-only Evidence Baseline & Execution Contract Freeze**.

A1 purpose:
- establish current portfolio eligibility;
- produce cache-only R3 evidence coverage baseline;
- produce cache-only R5 market-history baseline;
- define pure incremental history-window planning;
- inventory benchmark dependencies;
- quantify projected provider work without executing it;
- propose bounded R3/R5 pilot cohorts for the next checkpoint.

Mandatory Codex behavior before build:
- read the canonical post-K plan, cumulative handoff, architecture audit, A1 plan, Integration & Execution Plan, Research & Intelligence Architecture and relevant current implementation;
- perform a bounded planning verification only;
- identify only hard contradictions, reuse points and minimal file-change set;
- STOP only for a genuine safety/architecture blocker;
- otherwise proceed directly into A1 implementation in the same Codex task;
- no open-ended re-audit cycle.

A1 explicitly prohibits:
- Trendlyne execution;
- Angel One execution;
- NSE/provider execution;
- production mutation/migration;
- score/recommendation/sizing persistence;
- scheduler activation;
- AI activation;
- portfolio mutation;
- deployment;
- PR merge;
- automatic trading.

Post-PKR scoring safety must remain:
- unsupported methodology → METHODOLOGY_NOT_AVAILABLE + BLOCKED;
- missing/conflicting classification → REVIEW_REQUIRED + BLOCKED;
- completed K4 methodology → AVAILABLE + scoring execution PENDING_ADAPTER;
- no legacy GENERAL numeric scoring for K4;
- PHARMA_V1 and supported BANK scoring preserved;
- NBFC_LENDING fail-closed.

**Program A = IN PROGRESS (planning started).**
**A1 plan = FROZEN / IMPLEMENTATION NOT STARTED.**
**Provider execution = NOT AUTHORIZED.**


---

## Program A · A1 implementation status — 23 September 2026

### A1.1 — Planner / contract implementation

Commit:
- `a8ed4867801abee34d3d9ab84c9cbdadbf5ad287`

Status:
- COMPLETE / PASS.

Implemented:
- Program A eligibility resolver;
- deterministic R3 evidence-coverage planner;
- deterministic R5 market-history planner;
- pure incremental-history window planning;
- benchmark dependency inventory;
- projected provider-cost planner;
- bounded pilot-cohort proposal;
- explicit zero-provider / zero-budget safety state.

Important architectural result:
- completed K4 methodologies remain `AVAILABLE + PENDING_ADAPTER`;
- no K4 engine falls through to legacy GENERAL numeric scoring;
- unsupported/review-required methodology stays fail-closed.

### A1.2 — Real cache-only baseline materializer

Commit:
- `3534c2b69ccb14d3c73d6437b9685882ba1a03e6`

Status:
- IMPLEMENTATION COMPLETE / PASS.

Implemented:
- cache-only snapshot SQL using `BEGIN TRANSACTION READ ONLY`;
- local-only execution guard restricted to localhost / 127.0.0.1 port 54322;
- materialization of current Portfolio Coverage Registry rows into `ProgramAHoldingInput[]`;
- canonical R3 materialization for fundamentals, ownership, ratings applicability/evidence, documents, valuation and honest durability-missing state;
- R5 materialization from Angel One mapping state, stored candle bounds and existing market metrics;
- runtime benchmark evidence only for implemented NIFTY_BANK / NIFTY_PHARMA support;
- deterministic JSON + CLI-safe Markdown report;
- local command `bash scripts/program-a-a1-materialize-local.sh <local-portfolio-uuid> [YYYY-MM-DD]`.

Validation reported:
- 47 focused tests PASS;
- K-FINAL consolidated 39 tests PASS;
- TypeScript PASS;
- architecture guard PASS;
- changed-file lint PASS;
- build PASS;
- existing chunk-size warning only.

Real local execution:
- successfully materialized the six-holding `LOCAL UI Research Review` portfolio;
- eligible = 1;
- review required = 5;
- projected Trendlyne calls = 2;
- projected Angel One security requests = 1;
- actual provider calls = 0;
- budget consumed = 0;
- writes = 0.

Observed data gaps from the local run:
- classification coverage incomplete for five of six holdings;
- canonical business-durability materialization unavailable;
- authoritative portfolio weight remains owned by the client read model and is not persisted in the local database snapshot.

Safety:
- no Trendlyne call;
- no Angel One call;
- no NSE/provider call;
- no production access;
- no migration;
- no score/recommendation/sizing persistence;
- no scheduler/AI activation;
- no deployment;
- no merge;
- no trading.

A1 engineering implementation is complete. Formal full-portfolio closure requires either:
1. running the same cache-only materializer against the owner's full current local portfolio dataset, if present locally; or
2. explicitly accepting the six-holding local portfolio as the A1 runtime validation cohort and carrying full-portfolio data coverage into the next Program A execution checkpoint.

No additional architecture work is required for A1.


---

## Program A · A1 formal closure — 23 September 2026

Local portfolio inventory check confirmed that the current local Supabase instance contains only the small UI/test portfolios:
- `10000000-0000-4000-8000-000000000001` — `LOCAL UI Research Review`;
- `a1000000-0000-4000-8000-000000000001` — `Local UI Review`.

No full owner portfolio dataset is presently available in local Supabase.

Therefore the already-successful six-holding `LOCAL UI Research Review` execution is accepted as the A1 runtime validation cohort.

Accepted runtime result:
- eligible = 1;
- review required = 5;
- projected Trendlyne calls = 2;
- projected Angel One security requests = 1;
- actual provider calls = 0;
- actual budget consumed = 0;
- writes = 0.

A1 acceptance interpretation:
- A1's purpose was to prove the real cache-only materialization path and quantify current coverage gaps without provider execution;
- that objective is satisfied;
- absence of the full current portfolio in local Supabase is an environment/data-availability issue, not an A1 architecture or implementation blocker;
- full-portfolio breadth will be handled by subsequent Program A execution checkpoints when the appropriate local/current portfolio scope is available.

Final status:
- A1.1 = COMPLETE / PASS;
- A1.2 = COMPLETE / PASS;
- **Program A · A1 = COMPLETE / PASS / CLOSED**;
- Program A = IN PROGRESS;
- provider execution = STILL NOT AUTHORIZED.

Next step:
- plan/freeze the first bounded provider-backed Program A execution checkpoint;
- no provider execution until that next checkpoint is explicitly approved.


---

## Program A · A2 plan freeze — 23 September 2026

Canonical plan:
- `docs/PortfolioAI_PROGRAM_A_A2_BOUNDED_PROVIDER_PILOT_PLAN.md`.

A2 title:
- **Prerequisite-First Bounded Provider Pilot**.

A2 is the first provider-backed Program A checkpoint, but provider execution remains gated behind an exact generated PLAN and explicit owner approval.

A1 local runtime evidence showed:
- six-holding validation cohort;
- eligible = 1;
- review required = 5;
- main immediate blocker = incomplete canonical classification.

Therefore A2 sequence is frozen as:
1. A2A classification prerequisite pilot for at most five review-blocked securities;
2. re-materialize the A1 baseline;
3. A2B bounded R3 evidence pilot for at most three eligible securities;
4. A2C bounded R5 Angel One history pilot for at most three eligible securities;
5. re-materialize and validate;
6. stop.

Hard ceilings:
- A2A Trendlyne classification calls <= 5;
- A2B Trendlyne physical calls <= 6;
- A2A + A2B Trendlyne physical calls <= 10;
- A2C Angel One security requests <= 3;
- A2C benchmark requests <= 2;
- total Angel One historical requests <= 5;
- retries count toward ceilings.

Mandatory execution contract:
- PLAN = zero provider calls;
- Codex may implement and run PLAN only;
- EXECUTE requires exact owner-approved confirmation after ChatGPT audits the generated plan;
- local Supabase only;
- production execution prohibited.

A2 implementation must reuse existing provider control plane, leases, freshness, retry/accounting and idempotent persistence rather than direct ad-hoc provider calls.

Safety unchanged:
- no score/recommendation/sizing activation;
- no scheduler change;
- no AI activation;
- no deployment;
- no PR merge;
- no automatic trading.

**Program A · A1 = COMPLETE / PASS / CLOSED.**
**Program A · A2 plan = FROZEN / IMPLEMENTATION NOT STARTED.**
**Provider execution = NOT AUTHORIZED.**


---

## Program A · A2 implementation checkpoint — 23 September 2026

Implementation commit:
- `94335ffcd561df3f292129156c3913322f5465e1`

Status:
- implementation = COMPLETE / PASS;
- provider execution = NOT YET RUN;
- A2 formal closure = PENDING owner-approved staged execution + validation.

Implemented:
- deterministic A2 PLAN builder with SHA-256 plan ID and exact confirmation token;
- exact bounded A2A classification cohort;
- bounded A2B Complete Research cohort;
- bounded A2C incremental Angel One history cohort;
- local-only guards in controller and A2-specific Edge Function paths;
- existing provider budgets, leases, accounting, lineage and idempotent persistence reused;
- stale-plan/cache-drift guard;
- runtime call ceilings;
- classification conflict / ambiguous identity hard stops;
- A1 incremental history window passed into existing Angel One history adapter;
- CLI with explicit PLAN / EXECUTE modes.

Audited current local PLAN:
- plan ID `cc238e54b2d904c4298b9cdb29f4d02f13067dc2787d289a859e4e5471d995a3`;
- A2A classification cohort: ALIVUS, AUROPHARMA, BIOCON, HDFCBANK, SYNGENE;
- A2B provisional cohort: TORNTPHARM via reviewed four-call Complete Research capability;
- A2C provisional cohort: TORNTPHARM incremental history, 2026-09-12 through 2026-09-23;
- projected Trendlyne total = 9;
- projected Angel One total in the generated local plan = 1;
- actual calls/budget = 0;
- confirmation token `APPROVE_PROGRAM_A_A2_CC238E54B2D904C4`.

Critical staged-execution behavior:
- after A2A classification writes, A2 re-materializes the cache and rebuilds the plan;
- any classification change alters the plan fingerprint;
- execution therefore stops before A2B with `STALE_PLAN_REPLAN_REQUIRED`;
- a new PLAN and a new explicit owner approval are required before A2B/A2C;
- this prevents one approval from silently expanding into deeper evidence/history execution after classification state changes.

Validation reported:
- 52 focused application tests PASS;
- 143 Edge/provider-control tests PASS;
- K-FINAL regressions PASS;
- TypeScript PASS;
- architecture guard PASS;
- changed-file lint PASS;
- build PASS;
- no provider contacted during implementation.

Safety unchanged:
- local Supabase only;
- no production mutation;
- no score/recommendation/sizing activation;
- no scheduler/AI activation;
- no deployment;
- no merge;
- no trading.

**A2 implementation = PASS / READY FOR OWNER REVIEW OF A2A EXECUTION.**


---

## Program A · A2A first-run rejection diagnosis and contract correction — 23 September 2026

The owner-approved V2 A2A run stopped on its first action, ALIVUS, after one
successful Trendlyne `search_entities` provider attempt. No classification source
record, observation or decision was written, and A2B/A2C did not run.

Correlated local append-only audit evidence:
- ingestion run `c9c24be1-09b3-4ced-a398-7172a7ff756b`;
- ALIVUS run item `975c2264-6c30-4ca1-9128-52f6c2697c10`;
- item status `REJECTED`;
- exact safe reason `NO_EXACT_PROVIDER_IDENTITY`;
- attempted calls = 1, accepted records = 0;
- provider usage event outcome = `SUCCEEDED`, proving the transport/tool call completed;
- no `data_source_records` row exists for the run and the item metadata is empty.

Therefore the incident was not proven ambiguous. The provider response produced
zero candidates satisfying both the exact canonical ALIVUS ISIN and exact symbol
contract. The earlier implementation did not retain safe candidate-count
diagnostics, so the historical evidence cannot distinguish no parsed candidates,
symbol-only matches, ISIN-only matches or other non-exact candidates. No repeat
provider call was made merely to diagnose that missing historical detail.

Focused correction:
- exact canonical-ISIN plus exact-symbol matching remains mandatory and fail-closed;
- no symbol/name similarity fallback was introduced;
- `NO_EXACT_PROVIDER_IDENTITY`, `AMBIGUOUS_PROVIDER_IDENTITY` and
  `CLASSIFICATION_MISSING` now remain distinct from Edge audit through the A2 runner;
- rejected items retain only non-secret aggregate match counts, never raw provider payloads;
- rejected-only ingestion runs finish `FAILED`, rather than misleadingly `SUCCEEDED`;
- arbitrary provider text is collapsed to a safe generic code;
- the A2 plan contract advances to V3, invalidating the previous V2 plan approval.

Validation:
- pure classification matcher/rejection-path tests = PASS;
- runner safe-code propagation and zero-write rejection tests = PASS;
- A2 controller fingerprint, local-target, budget and stage-boundary regressions = PASS;
- focused application regressions = 39 PASS;
- Edge/provider-control suite = 147 PASS;
- TypeScript, architecture guard, changed-file lint and production build = PASS;
- no live provider call was made by this correction.

Fresh zero-provider-call plan:
- version `PROGRAM_A_A2_BOUNDED_PILOT_V3`;
- plan ID `d0e5319836c579567f94cce1ad25c0485de77b0f9cc46a29d36d53f0545836de`;
- confirmation token `APPROVE_PROGRAM_A_A2_D0E5319836C57956`;
- exact A2A cohort remains ALIVUS, AUROPHARMA, BIOCON, HDFCBANK, SYNGENE;
- all five canonical ISIN prerequisites are `READY`;
- A2A Trendlyne ceiling = 5, actual PLAN calls/budget/writes = 0.

Remaining sequence:
1. generate and review a fresh zero-provider-call V3 PLAN;
2. obtain explicit owner approval for its exact plan ID/token;
3. run classification-only A2A;
4. verify local canonical writes and rematerialized A1 baseline;
5. require `STALE_PLAN_REPLAN_REQUIRED` before any A2B/A2C execution.

**Program A · A2 remains IN PROGRESS.**
**The prior V2 plan approval must not be reused.**

---

## Program A · A2A V3 safe-shape diagnosis and V4 replan — 23 September 2026

The owner-executed V3 A2A attempt again stopped on ALIVUS after one successful
Trendlyne tool attempt and before any local classification write. A2B and A2C did
not run.

Correlated local audit evidence:
- ingestion run `8adbb1bb-213e-431b-b310-7b91928934e4`;
- ALIVUS run item `ae073f41-3492-4228-b1b5-82374114e19b`;
- run status `FAILED`, attempted = 1, accepted = 0, rejected = 1, failed = 0;
- item status `REJECTED`, safe reason `NO_EXACT_PROVIDER_IDENTITY`, attempted calls = 1, accepted records = 0;
- safe item counts: candidates = 0, symbol matches = 0, ISIN matches = 0,
  exact matches = 0, classified exact matches = 0.

This audit inspection made zero provider calls and no writes. The V3 metadata
proved that the parser produced no candidates, but it could not distinguish a
valid empty provider table from an unrecognized response envelope or table shape.
Raw provider content was not retained, so the historical V3 response cannot be
reconstructed and no unsupported claim about Trendlyne identity data is made.

Focused V4 correction:
- recognizes the reviewed marked table, plain Markdown pipe tables, compact pipe
  delimiters, and JSON string envelopes under `markdown_data`, `result`, or `data`;
- locates required fields by normalized header name instead of fixed column offset;
- preserves exact canonical symbol plus exact canonical ISIN matching;
- records only safe parse-shape metadata: parse state, envelope class, marker
  presence, nonempty-line count, pipe-line count and parsed-row count;
- distinguishes valid empty results from nonempty unrecognized response shapes;
- rejects an unrecognized shape as `PROVIDER_SCHEMA_MISMATCH`, with zero writes;
- retains `NO_EXACT_PROVIDER_IDENTITY` for a successfully parsed table with no
  exact candidate and retains all other distinct rejection reasons;
- advances the plan contract to V4, invalidating the V3 plan approval.

Validation:
- Edge/provider-control suite = 150 PASS;
- focused A1/A2 application regressions = 20 PASS;
- runner safe-code propagation suite = 6 PASS;
- TypeScript and architecture guard = PASS;
- PLAN generation made zero provider calls and consumed zero provider budget.

Fresh zero-provider-call V4 plan:
- version `PROGRAM_A_A2_BOUNDED_PILOT_V4`;
- plan ID `c35d2b1c8d39c6ea7c065fc3dfa63f4f56e2c4a95cb581e5e024a7342197c29e`;
- confirmation token `APPROVE_PROGRAM_A_A2_C35D2B1C8D39C6EA`;
- exact A2A cohort remains ALIVUS, AUROPHARMA, BIOCON, HDFCBANK, SYNGENE;
- all five canonical identity prerequisites are `READY`;
- HDFCBANK uses canonical local ISIN `INE040A01034`;
- A2A Trendlyne ceiling = 5; total planned Trendlyne = 9; Angel One = 1;
- actual PLAN provider calls, budget consumed and writes = 0.

Remaining sequence:
1. review and explicitly approve the exact V4 plan ID/token;
2. run classification-only A2A;
3. inspect the first item safe counts and new parse-shape metadata;
4. verify any accepted local canonical writes and rematerialized A1 baseline;
5. require `STALE_PLAN_REPLAN_REQUIRED` before any A2B/A2C execution.

**Program A · A2 remains IN PROGRESS.**
**No V2 or V3 approval may be reused.**

---

## Program A · A2A V4 execution result — 23 September 2026

The owner explicitly approved V4 plan
`c35d2b1c8d39c6ea7c065fc3dfa63f4f56e2c4a95cb581e5e024a7342197c29e`
and its exact confirmation token. The first invocation stopped before dispatch
because the runner process lacked its three required local environment variables;
that invocation made zero provider calls. The same approved plan was then invoked
with credentials resolved only from the running local Supabase instance and local
Vault, without printing or persisting them.

Bounded execution result:
- status `PARTIAL_STOPPED`;
- stop reason `PROVIDER_SCHEMA_MISMATCH`;
- Trendlyne calls = 1; Angel One calls = 0; retries = 0;
- successful local classification writes = 0;
- score, recommendation and sizing writes = 0;
- A2B and A2C did not execute.

Correlated local audit evidence:
- ingestion run `f38aa9e7-5cdc-4062-b71f-05810cf6609e`;
- ALIVUS item `f2eba073-3b49-4b1e-a542-d464596d22e5`;
- run status `FAILED`, attempted = 1, accepted = 0, rejected = 1, failed = 0;
- item status `REJECTED`, safe reason `PROVIDER_SCHEMA_MISMATCH`;
- provider usage outcome `SUCCEEDED`, retry attempt = 0, internal units = 1;
- source records written for this run = 0;
- safe parse shape: `UNRECOGNIZED_RESPONSE`, envelope `PLAIN_TEXT`, data marker
  present, end marker absent, nonempty lines = 1, pipe-delimited lines = 0,
  parsed candidate rows = 0.

Conclusion:
- this is not evidence of an ambiguous identity or of no exact ALIVUS identity;
- Trendlyne returned a successful nonempty one-line response whose shape is not
  recognized by the approved parser;
- raw provider content was deliberately not retained, so its schema cannot be
  reconstructed from this audit and must not be guessed;
- existing local K1 evidence shows Trendlyne has previously returned nested
  `markdown_data` and non-header pipe data for a different capture, but that does
  not prove the V4 ALIVUS response used the same schema.

The V4 approval is consumed and must not be reused. Before another provider call,
the response contract must be established through provider capability/schema
evidence or a newly reviewed safe diagnostic plan. A fresh fingerprinted plan and
explicit owner approval are required.

**Program A · A2 remains IN PROGRESS at A2A.**
**A2B and A2C remain blocked by the classification stage boundary.**

---

## Program A · A2A Trendlyne contract recovery and closure — 23 September 2026

Owner authorization allowed bounded Trendlyne calls needed to diagnose and clear
the A2A classification blockade. Provider capability discovery established the
current `search_entities` contract: exact identity/classification records are
returned under `data`, using either a `status/data` text table or the documented
JSON `data[]` envelope. The prior adapter expected an obsolete pipe-table shape.

Verified provider behavior:
- symbol-only `ALIVUS` returned a valid empty result;
- canonical ISIN search was semantic and returned a non-exact candidate, which
  confirms that ISIN may never be accepted without exact result reconciliation;
- canonical company-name search returned ALIVUS with exact symbol
  `ALIVUS` and exact ISIN `INE03Q201024`;
- HDFCBANK returned the documented identity fields and exact ISIN
  `INE040A01034`.

Implemented contract correction:
- A2 classification actions bind canonical company name, symbol, ISIN and
  prerequisite readiness into the plan fingerprint;
- the runner sends the fingerprinted canonical name to the local Edge adapter;
- the Edge adapter verifies that the requested name still equals local canonical
  identity before provider dispatch;
- the parser supports current `status/data`, documented JSON `data[]`, reviewed
  Markdown wrappers and valid empty results;
- candidate acceptance still requires one exact symbol plus exact canonical ISIN
  and non-null sector/industry;
- raw source values remain immutable and auditable;
- safe execution accounting now retains accepted evidence-write counts even when
  a new mapping pair stops the run for review.

Canonical normalization correction:
- migration `20260923111000_add_program_a_canonical_taxonomy_prerequisites.sql`
  materializes the stable Banking/Pharma sector and industry identities required
  by the reviewed mappings, and normalizes pre-existing local fixture codes
  without replacing those identities;
- migration `20260923110816_use_normalized_current_security_classification.sql`
  makes the security-invoker canonical view prefer reviewed `normalized_value`
  while retaining raw `text_value` in immutable observations;
- the adapter resolves reviewed mapping IDs to canonical sector/industry names;
- a mapping-authority change creates a new hashed source-record version rather
  than updating prior evidence;
- exact reviewed mappings were added through migrations for:
  - `Pharmaceuticals & Biotechnology / Pharmaceuticals` →
    `Pharma / Pharmaceuticals`;
  - `Pharmaceuticals & Biotechnology / Biotechnology` →
    `Pharma / Pharmaceuticals`, supported by the existing BIOCON Gate J G10.3
    classification lock;
  - `Banking and Finance / Banks` → `Banking / Private Sector Bank`, supported by
    the existing HDFCBANK canonical classification;
- routing now recognizes the canonical `Private Sector Bank` industry as BANK,
  alongside the legacy generic `Banks` token. No BANK_NBFC scoring formula changed.

Bounded A2A results:
- V5 proved exact ALIVUS resolution and stopped on its new mapping pair;
- V7 normalized ALIVUS and AUROPHARMA, then stopped on BIOCON's reviewed pair;
- V8 normalized BIOCON, then stopped on HDFCBANK's reviewed pair;
- V9 normalized HDFCBANK and SYNGENE and stopped at
  `STALE_PLAN_REPLAN_REQUIRED` before A2B;
- every provider call had zero retries;
- no Angel One call, score write, recommendation write or sizing write occurred.

Final A2A canonical **sector/industry normalization** cohort:
- ALIVUS → `Pharma / Pharmaceuticals`;
- AUROPHARMA → `Pharma / Pharmaceuticals`;
- BIOCON → `Pharma / Pharmaceuticals`;
- HDFCBANK → `Banking / Private Sector Bank`;
- SYNGENE → `Pharma / Pharmaceuticals`;
- TORNTPHARM remains `PHARMA / PHARMACEUTICALS` from its prior authority.

IMPORTANT: these A2A values are only the canonical sector/industry layer. They are **not** the final Pharma research subprofile or scoring-methodology classification.

Post-A2A V10 zero-call plan:
- plan ID `162f683dbcd3701bb1f9b0289bf70de9c24ef184f0805d91da47249129842626`;
- confirmation token `APPROVE_PROGRAM_A_A2_162F683DBCD3701B`;
- A2A action count = 0;
- A2B proposes one four-call ALIVUS Complete Research action;
- A2C proposes three security-history calls and one NIFTY Bank benchmark call;
- actual PLAN calls, budget and writes = 0.

Validation:
- the five A2 migrations applied to local Supabase only;
- the complete migration history replayed successfully in a shadow database and
  `supabase db diff --local` reported `No schema changes found`;
- focused provider-contract, parser, controller, cache-materializer and BANK/NBFC
  portability tests passed;
- Edge test suite, typecheck, architecture guard, changed Edge lint and production
  build passed.
- no production migration, deployment or merge occurred.

**Program A · A2A = COMPLETE / PASS / CLOSED.**
**Program A · A2 remains IN PROGRESS; A2B and A2C require their separately reviewed V10 execution boundary.**


---

## ChatGPT audit confirmation — Program A · A2A closure — 23 September 2026

Remote audit range:
- base: `b30db340c8204e98afe15f0eda220cf699d70fe5`
- closure tip: `5367f3ea53561938ea4a11dcbc1ac0c279372b04`
- three commits reviewed on `program-a-evidence-coverage`.

Audit conclusion:
- A2A implementation and local execution are consistent with the frozen prerequisite-first Program A plan;
- the Trendlyne classification adapter now parses the current provider response contract rather than the obsolete table-only shape;
- provider identity reconciliation remains exact symbol + canonical ISIN and now also fingerprints canonical company name;
- provider source values remain immutable while reviewed canonical normalization is stored separately;
- reviewed mapping-pair additions are explicit and fail-closed rather than ticker inference;
- current canonical view prefers reviewed `normalized_value` while retaining original `text_value`;
- canonical `Private Sector Bank` routes to BANK_NBFC/BANK without enabling NBFC_LENDING;
- no BANK/NBFC scoring formula changed;
- accepted local evidence writes are now accounted even when a new mapping pair causes a review stop;
- A2 stage isolation held: after the A2A classification changes, execution stopped before A2B/A2C and a fresh plan was required.

Reviewed local-only migrations:
- `20260923110816_use_normalized_current_security_classification.sql`;
- `20260923111000_add_program_a_canonical_taxonomy_prerequisites.sql`;
- `20260923111115_add_reviewed_trendlyne_pharma_mapping.sql`;
- `20260923111330_add_reviewed_trendlyne_biotechnology_mapping.sql`;
- `20260923111553_add_reviewed_trendlyne_bank_mapping.sql`.

These migrations were applied to local Supabase only. Codex reported full migration shadow replay PASS and `supabase db diff --local` = `No schema changes found`. No production migration was applied.

Final A2A cohort state:
- ALIVUS → Pharma / Pharmaceuticals;
- AUROPHARMA → Pharma / Pharmaceuticals;
- BIOCON → Pharma / Pharmaceuticals;
- HDFCBANK → Banking / Private Sector Bank;
- SYNGENE → Pharma / Pharmaceuticals.

Fresh V10 zero-call plan after A2A:
- plan ID `162f683dbcd3701bb1f9b0289bf70de9c24ef184f0805d91da47249129842626`;
- confirmation token `APPROVE_PROGRAM_A_A2_162F683DBCD3701B`;
- A2A actions = 0;
- A2B proposal = one ALIVUS Complete Research action / 4 Trendlyne calls;
- A2C proposal = 4 Angel One calls;
- plan-generation provider calls = 0;
- plan-generation budget consumed = 0.

Safety audit:
- no production mutation;
- no production migration;
- no deployment;
- no PR merge;
- no score/recommendation/sizing activation;
- no scheduler/AI activation;
- no trading;
- A2B and A2C remain separately approval-gated.

**ChatGPT audit verdict: Program A · A2A = COMPLETE / PASS / CLOSED.**
**Program A · A2 = IN PROGRESS.**
**Current next boundary = separate review of V10 A2B and A2C; neither is authorized yet.**


---

## Critical Pharma classification hierarchy clarification — 23 September 2026

This clarification is canonical and must be preserved in all future Program A/B work.

### A2A classification is NOT the Pharma scoring subprofile

Program A · A2A resolved the broad canonical provider taxonomy needed for routing prerequisites:

```text
Provider classification
        ↓
Canonical Sector / Industry
```

For Pharma holdings this currently produces a broad canonical identity such as:

```text
Sector:   Pharma
Industry: Pharmaceuticals
```

That result is **necessary but not sufficient** for Pharma methodology execution.

The Pharma architecture built through Gates G/H/I/J must retain the deeper business-model classification layer:

```text
Sector
  ↓
Industry
  ↓
Pharma subprofile / business-model classification
  ↓
PHARMA_V1 methodology contract
  ↓
Subprofile-specific evidence requirements
  ↓
Deterministic scoring
  ↓
Recommendation policy
```

Canonical Pharma subprofiles remain distinct:

- `API_BULK_DRUGS`
- `DOMESTIC_FORMULATIONS`
- `GLOBAL_GENERICS`
- `BIOPHARMA_BIOSIMILARS`
- `CDMO_CRAMS`

These subprofiles are **not interchangeable** and must not be collapsed into generic `Pharma / Pharmaceuticals`.

### ALIVUS example

Current A2A result:

```text
ALIVUS
→ Sector/Industry normalization:
  Pharma / Pharmaceuticals
```

This does **not** establish ALIVUS's Pharma scoring subprofile.

For downstream Pharma research/scoring, the separate Pharma subprofile authority must resolve the company to its approved business-model classification. The intended current classification discussed by the owner is:

```text
ALIVUS
→ Health Care sector context
→ Pharma industry
→ API_BULK_DRUGS Pharma subprofile
→ PHARMA_V1 / API_BULK_DRUGS methodology
```

A2A must never overwrite, infer, or replace that subprofile authority merely because the provider returns a broad `Pharmaceuticals` industry.

### Architectural rule

The hierarchy is permanently:

```text
Sector          = macro context
Industry        = minimum methodology-routing context
Basic Industry / business model = refinement
Pharma subprofile = Pharma-specific metric/applicability/valuation authority
Company evidence = scoring evidence
Score           = deterministic assessment
Recommendation  = downstream action logic
```

Therefore:

- A2A owns provider-to-canonical sector/industry normalization only;
- Pharma subprofile authority remains separate;
- `Pharma / Pharmaceuticals` must never be treated as sufficient authority for choosing the Pharma scoring formula;
- a Pharma security without a resolved approved subprofile must fail closed before subprofile-specific scoring;
- Program A evidence acquisition must respect the resolved Pharma subprofile's required domains;
- Program B / R6 must execute the scorer associated with the approved Pharma subprofile, not a generic Pharmaceuticals scorer;
- no ticker-specific runtime workaround may replace the canonical subprofile contract.

### Current A2A closure interpretation

A2A remains COMPLETE / PASS / CLOSED because its scope was broad classification prerequisite normalization.

Its closure means:

```text
Provider classification path        = proven
Canonical sector/industry mapping    = proven
Exact identity reconciliation        = proven
```

It does **not** mean:

```text
Pharma subprofile classification     = newly proven by A2A
Pharma subprofile methodology        = replaced by broad industry
Pharma scoring readiness             = automatically established
```

The previously built Pharma subprofile architecture remains authoritative and must be consulted before A2B evidence selection and, especially, before Program B / R6 scoring.

**This distinction must not be removed or simplified in future handoffs, plans, scoring adapters, or UI contracts.**

---

## Program A · A2B Pharma subprofile prerequisite wiring — 23 September 2026

A focused A2B contract correction now binds Pharma Complete Research actions to
the canonical active reviewed subprofile assignment before provider dispatch.

Implemented:
- the cache-only snapshot reads persisted `research_subprofile_assignments` for
  held securities; the provisional candidate registry is not an input;
- the existing fail-closed Pharma assignment resolver determines whether the
  assignment is active and reviewed;
- the resolved assignment version must match the existing effective subprofile
  contract authority;
- the A2B action binds the resolved subprofile, `REVIEWED` assignment state,
  effective contract version and registered Gate-J methodology version into the
  plan fingerprint;
- missing, provisional, disputed, conflicting, inactive or contract-mismatched
  Pharma authority produces no A2B provider action;
- execution independently refuses a malformed Pharma A2B action with
  `PHARMA_SUBPROFILE_PREREQUISITE_MISSING` before dispatch;
- non-Pharma A2B behavior and the indivisible four-call Complete Research
  capability are unchanged.

Fresh local cache-only V11 plan:
- plan ID `281076d2367ee4e8b6c799a56454f4d0da2da1522973ed453e5bf4524cf78b5e`;
- confirmation token `APPROVE_PROGRAM_A_A2_281076D2367EE4E8`;
- A2A action count = 0;
- A2B = ALIVUS / `API_BULK_DRUGS` / `API_BULK_DRUGS_V1` /
  `PHARMA_API_G10_1_NUMERIC_METHODOLOGY_V1_CANDIDATE` / four calls;
- PLAN provider calls, budget and writes = 0;
- A2B and A2C were not executed.

Validation:
- focused A1/A2, assignment, contract and Gate-J portability suite: 38 tests PASS;
- TypeScript: PASS;
- architecture guard: PASS;
- changed-file lint: PASS;
- production build: PASS with the inherited chunk-size warning.

**Program A · A2B remains PLANNED / NOT EXECUTED pending review of the new V11 plan.**

### A2 stage-specific execution authority

The local A2 execution boundary now requires an explicit approved stage:

```text
EXECUTE_STAGE <portfolio-id> <date> <A2A|A2B|A2C> <plan-id> <confirmation-token>
```

Execution filters the fingerprinted plan to that stage and refuses before any
provider dispatch when stage authority is missing, invalid, or has no planned
actions. Full-plan stale-plan and provider-ceiling checks remain in force, as do
the A2A identity and A2B reviewed-Pharma-subprofile prerequisites. A successful
stage run rematerializes the cache-only A1 summary and stops; it does not advance
to another stage.

The fresh zero-provider V11 plan remains unchanged:
- plan ID `281076d2367ee4e8b6c799a56454f4d0da2da1522973ed453e5bf4524cf78b5e`;
- A2A action count = 0;
- the sole A2B action is ALIVUS, reviewed `API_BULK_DRUGS`, contract
  `API_BULK_DRUGS_V1`, methodology
  `PHARMA_API_G10_1_NUMERIC_METHODOLOGY_V1_CANDIDATE`, four Trendlyne calls;
- A2C remains separately planned and is not authorized by A2B execution;
- PLAN provider calls, budget and writes = 0.

Stage-boundary validation:
- focused A1/A2, Pharma assignment, contract and Gate-J portability suite:
  39 tests PASS;
- TypeScript: PASS;
- architecture guard: PASS;
- changed-file lint and shell syntax: PASS;
- production build: PASS with the inherited chunk-size warning.

**The stage-boundary implementation is ready for the conditionally approved
local A2B-only execution. A2C remains NOT EXECUTED and requires a separate fresh
plan and approval.**

### A2B Trendlyne provider-identity prerequisite

The first stage-scoped A2B attempt correctly stopped before dispatch because
ALIVUS had no canonical `TRENDLYNE_MCP` provider identity observation. It used
zero provider calls and made zero writes.

The V12 contract now binds provider-identity readiness and the provider
instrument ID, when available, into each A2B action and plan fingerprint. States
are explicit: `VERIFIED_EXISTING_IDENTITY`, `IDENTITY_DISCOVERY_REQUIRED`, and
`BLOCKED_IDENTITY_CONFLICT`; successful discovery returns
`VERIFIED_DURING_PREREQUISITE_DISCOVERY`.

For a missing identity, the bounded local prerequisite performs two calls:
exact `search_entities` reconciliation against canonical name, NSE symbol and
ISIN, followed by an overview call that supplies and revalidates the stable
Trendlyne stock ID. It persists immutable raw provenance and an idempotent
`MATCHED` `security_identity_observations` row. Ambiguity, symbol/ISIN/name/BSE
conflict, or an existing conflicting matched identity fails closed. The normal
four-call Complete Research operation then runs separately against that verified
ID, for a truthful six-call A2B maximum.

Fresh zero-provider V12 plan:
- plan ID `5cd6565e901131bb1a58e5003cba7b5ef7834f258f46087b5c0bde1e27914b25`;
- confirmation token `APPROVE_PROGRAM_A_A2_5CD6565E901131BB`;
- A2A action count = 0;
- sole A2B action = ALIVUS / reviewed `API_BULK_DRUGS` /
  `API_BULK_DRUGS_V1` /
  `PHARMA_API_G10_1_NUMERIC_METHODOLOGY_V1_CANDIDATE`;
- provider identity state = `IDENTITY_DISCOVERY_REQUIRED`;
- bounded A2B Trendlyne calls = 6; PLAN calls and writes = 0;
- A2C remains separately planned and outside A2B execution authority.


---

## Pharma runtime activation guard — canonical reminder — 23 September 2026

A dedicated canonical guard has been added:

- `docs/PortfolioAI_PHARMA_SUBPROFILE_RUNTIME_ACTIVATION_GUARD.md`

Reason:
- all five Pharma methodology authorities exist;
- broad A2A `Pharma / Pharmaceuticals` normalization is not sufficient for Pharma scoring;
- current live Pharma scoring still routes broadly through the parent `PHARMA_V1` path and does not yet safely resolve the reviewed Pharma subprofile before selecting methodology.

Hard rule:
- no reviewed Pharma subprofile → no numeric score;
- provisional/disputed/conflicting Pharma subprofile → no numeric score;
- no cross-subprofile band borrowing;
- no generic Pharma fallback scorer;
- Program B / R6 must implement a focused Pharma runtime adapter before general Pharma scoring activation.

Current reviewed/unresolved examples:
- ALIVUS → API_BULK_DRUGS;
- AUROPHARMA → GLOBAL_GENERICS;
- TORNTPHARM → DOMESTIC_FORMULATIONS;
- BIOCON → provisional BIOPHARMA_BIOSIMILARS only; blocked until reviewed/persisted;
- SYNGENE → provisional CDMO_CRAMS only; blocked until reviewed/persisted.

This guard must be checked explicitly before A2B evidence selection where subprofile-specific evidence matters and must be satisfied before Program B / R6 score execution.


---

## Program A · A2B successful bounded execution and closure — 24 September 2026

The conditionally approved local A2B-only execution completed successfully after
the V12 provider-identity prerequisite was implemented.

Implementation / closure commit:
- `2b76b93c557d74cb4a6b00ad9518cd8e17b7cd6b`
- commit intent: bounded Trendlyne identity discovery + provider-identity-aware A2B
  planning/execution for ALIVUS;
- no database migration was created;
- no production mutation, deployment or merge occurred.

Fresh approved V12 plan:
- plan ID
  `5cd6565e901131bb1a58e5003cba7b5ef7834f258f46087b5c0bde1e27914b25`;
- confirmation token
  `APPROVE_PROGRAM_A_A2_5CD6565E901131BB`;
- A2A actions = 0;
- A2B actions = exactly one: ALIVUS;
- ALIVUS authority remained:
  - research profile: `PHARMA_V1`;
  - reviewed subprofile: `API_BULK_DRUGS`;
  - assignment state: `REVIEWED`;
  - contract: `API_BULK_DRUGS_V1`;
  - methodology:
    `PHARMA_API_G10_1_NUMERIC_METHODOLOGY_V1_CANDIDATE`;
- provider identity state before execution:
  `IDENTITY_DISCOVERY_REQUIRED`;
- bounded A2B Trendlyne ceiling = 6 calls;
- PLAN provider calls and writes = 0;
- A2C remained outside the A2B execution authority.

### Provider-identity resolution result

A2B first established ALIVUS's stable Trendlyne identity through a separate,
bounded prerequisite path.

Identity discovery:
1. `SEARCH_ENTITIES` using canonical company name, symbol and ISIN;
2. `GET_OVERVIEW_NEWS_CORP_EVENTS` to obtain and independently revalidate the
   stable provider stock ID.

Exact reconciliation basis:
- canonical security name;
- exact NSE symbol `ALIVUS`;
- exact ISIN `INE03Q201024`;
- Overview identity consistency;
- company-name normalization;
- BSE-code consistency where available;
- no conflicting existing `MATCHED` provider identity.

Verified provider identity:
- state: `VERIFIED_DURING_PREREQUISITE_DISCOVERY`;
- Trendlyne provider instrument ID: `606572`;
- observed company: `Alivus Life Sciences Ltd.`;
- symbol: `ALIVUS`;
- ISIN: `INE03Q201024`;
- exchange / series: `NSE / EQ`;
- evidence status: `MATCHED`;
- confidence: `1.0000`.

The identity path persisted:
- immutable `data_source_records` provenance;
- canonical `security_identity_observations` evidence;
- idempotent reuse of the same identity on later runs;
- fail-closed handling for ambiguity or conflict.

### Actual A2B provider execution

Execution completed with:
- status: `SUCCEEDED`;
- Trendlyne calls = 6;
- Angel One calls = 0;
- retries = 0;
- successful local writes reported by the bounded runner = 6;
- score writes = 0;
- recommendation writes = 0;
- sizing writes = 0;
- A2C execution = 0.

Call sequence:
1. `SEARCH_ENTITIES` — identity discovery — succeeded;
2. `GET_OVERVIEW_NEWS_CORP_EVENTS` — identity verification — succeeded;
3. `GET_OVERVIEW_NEWS_CORP_EVENTS` — Complete Research fundamentals — succeeded;
4. `GET_PARAMETER_VALUES_MULTI_STOCK` — detailed structured metrics — succeeded;
5. `GET_OWNERSHIP_DEALS_INSIDER_SAST` — ownership / pledge — succeeded;
6. `GET_DOCUMENT_SEARCH_RESULTS` — document/evidence discovery — succeeded.

No retry was required.

The successful local-write count represents:
- two identity/provenance writes;
- four accepted Complete Research domains.

### ALIVUS evidence added

Canonical local evidence captured from the A2B refresh includes:
- Revenue TTM;
- Net profit TTM;
- CFO annual;
- ROE annual;
- ROCE annual;
- PE TTM;
- provider market capitalisation;
- PBV observation retained as `CONFLICTING`;
- promoter ownership;
- FII/FPI ownership;
- DII ownership;
- mutual-fund ownership;
- public ownership;
- promoter pledge;
- one research document with provider source appearance;
- verified Trendlyne provider identity and immutable provenance.

The evidence architecture correctly retains point observations as point
observations. It does not promote them into multi-period Pharma contract evidence
without the required history.

### API_BULK_DRUGS mandatory evidence still missing

After A2B, the effective `API_BULK_DRUGS_V1` contract still reports these
mandatory items as missing:

- `PHARMA_REVENUE_GROWTH_HISTORY`;
- `PHARMA_OPERATING_MARGIN_HISTORY`;
- `PHARMA_ROCE_HISTORY`;
- `PHARMA_PAT_EPS_HISTORY`;
- `PHARMA_CASH_CONVERSION_HISTORY`;
- `PHARMA_BALANCE_SHEET_LEVERAGE`;
- `PHARMA_REGULATORY_SITE_STATUS`;
- `PHARMA_API_CUSTOMER_CONCENTRATION`;
- `PHARMA_API_CAPACITY_UTILIZATION`.

This is expected and correct. A2B proved current evidence acquisition, identity
resolution, provenance, canonical mapping and subprofile-aware planning; it did
not falsely infer multi-period or issuer-disclosed evidence from one current
snapshot.

### Post-A2B A1 baseline

Rematerialized cache-only baseline:
- total holdings = 6;
- eligible = 6;
- review required = 0;
- methodology unavailable = 0.

### Validation and ChatGPT audit

Codex-reported validation:
- focused A1/A2 and Pharma authority tests: PASS;
- TypeScript: PASS;
- architecture guard: PASS;
- changed-file ESLint: PASS;
- shell syntax: PASS;
- production build: PASS with the inherited chunk-size warning;
- `git diff --check`: PASS;
- secret check: PASS.

ChatGPT subsequently audited pushed commit
`2b76b93c557d74cb4a6b00ad9518cd8e17b7cd6b` and confirmed:

- A2B call budgeting is truthful:
  - identity discovery required → 6-call ceiling;
  - verified existing identity → 4-call ceiling;
- provider identity readiness participates in the plan fingerprint;
- conflicting provider identities block A2B;
- exact symbol + ISIN reconciliation remains fail-closed;
- canonical provider identity is persisted through the existing Stage-7 identity
  architecture;
- A2B runner accounts identity calls and research calls together;
- A2B stage authority remains isolated from A2C;
- ALIVUS remains bound to the reviewed `API_BULK_DRUGS` methodology authority;
- no generic Pharma fallback was introduced;
- no score, recommendation or sizing path was activated.

One non-blocking implementation note:
- the new local `resolve-trendlyne-identity` Edge function does not currently
  require a separate `supabase/config.toml` entry for the tested authenticated
  local flow and executed successfully;
- this should only be revisited if a real local-function configuration problem
  appears later.

### Formal status after A2B

```text
Program A
├── A1   COMPLETE / PASS / CLOSED
├── A2A  COMPLETE / PASS / CLOSED
├── A2B  COMPLETE / PASS / CLOSED
└── A2C  NOT EXECUTED
```

**Program A · A2B = COMPLETE / PASS / CLOSED.**

Program A · A2 remains IN PROGRESS only because A2C has not yet executed.

---

## Current next boundary — A2C fresh post-A2B plan required — 24 September 2026

A2C is the separately approval-gated Angel One market-history pilot.

Its purpose is to fill bounded R5 market-history / benchmark gaps required for
later deterministic momentum and risk evidence. It must not perform scoring,
recommendation, sizing or any Program-B runtime activation.

Important rule:
- do not reuse pre-A2B plan
  `5cd6565e901131bb1a58e5003cba7b5ef7834f258f46087b5c0bde1e27914b25`;
- provider identity and research-evidence state changed during A2B, therefore a
  fresh post-A2B PLAN is required before A2C approval.

Next sequence:
1. rematerialize the post-A2B cache-only baseline;
2. generate a fresh V12 A2 plan;
3. inspect only the A2C actions:
   - exact security-history targets;
   - requested date windows;
   - benchmark-history actions;
   - Angel One call count;
4. confirm A2A actions remain zero and no A2B action needs another refresh;
5. approve A2C separately;
6. execute `EXECUTE_STAGE ... A2C ...`;
7. stop after A2C and rematerialize again;
8. then determine whether Program A is fully COMPLETE / PASS / CLOSED.

A2C restrictions remain:
- no Trendlyne execution unless separately required by a newly reviewed plan;
- no scoring;
- no recommendation;
- no position sizing;
- no persistence of scores/recommendations/sizing;
- no scheduler or AI activation;
- no production mutation;
- no deployment;
- no PR merge;
- no trading.

**Current project boundary = fresh post-A2B A2C planning and review.**


---

## Program A · A2C first execution partial stop and canonical BANK guard correction — 24 September 2026

The first A2C execution under V13 stopped safely after two successful Angel One
security-history actions.

Executed V13 plan:
- plan ID `db9e0e5d9e59e8cd1f187174027088203c965d4f32f861140db7b494fbf4a4af`;
- confirmation token `APPROVE_PROGRAM_A_A2_DB9E0E5D9E59E8CD`;
- execution status `PARTIAL_STOPPED`;
- actual Angel One calls = 2;
- Trendlyne calls = 0;
- retries = 0;
- successful local writes = 492;
- score / recommendation / sizing writes = 0.

Successful actions:
- AUROPHARMA market history:
  - 246 candles stored;
  - earliest `2025-09-24`;
  - latest `2026-09-22`;
  - requested one-year window remained incomplete through `2026-09-24`;
- HDFCBANK market history:
  - 246 candles stored;
  - earliest `2025-09-24`;
  - latest `2026-09-22`;
  - requested one-year window remained incomplete through `2026-09-24`.

Safe-stop blocker:
- NIFTY_BANK benchmark dispatch did not occur;
- the legacy guard in `refresh-bank-benchmark` accepted only
  `Banking / Banks`;
- HDFCBANK's reviewed canonical classification is
  `Banking / Private Sector Bank`;
- this is a compatibility defect between the old benchmark guard and the already
  approved canonical BANK routing authority, not a reason to route HDFCBANK to
  NBFC_LENDING;
- TORNTPHARM did not execute because A2C stopped immediately at this blocker.

Post-stop fresh zero-provider plan:
- plan ID `be56e35fc3bd3e4bccd0816258c3d37cf080bcdb365549c12f92b9c9a363f9ee`;
- confirmation token `APPROVE_PROGRAM_A_A2_BE56E35FC3BD3E4B`;
- AUROPHARMA → incremental `2026-09-17 → 2026-09-24`;
- HDFCBANK → incremental `2026-09-17 → 2026-09-24`;
- NIFTY_BANK → full benchmark history `2025-09-24 → 2026-09-24`;
- TORNTPHARM → incremental `2026-09-12 → 2026-09-24`;
- PLAN provider calls = 0.

ChatGPT audited pushed V13 commit
`703e028f2a9b3b9fcfade6320ffe0ae8ae066b59` and confirmed:
- A2C physical Angel One calls are scope-bound with no numeric execution ceiling;
- approved target scope remains bounded;
- a 61-second cooldown is enforced between Angel One A2C dispatches;
- the NIFTY_BANK blocker is the stale exact industry guard in the benchmark Edge
  function.

Focused correction implemented on `program-a-evidence-coverage`:
- new shared helper:
  `supabase/functions/_shared/bank-benchmark-authority.ts`;
- new focused tests:
  `supabase/functions/_shared/bank-benchmark-authority.test.ts`;
- benchmark guard now allows only:
  - `Banking / Banks`;
  - `Banking / Private Sector Bank`;
- NBFC lending, unsupported Banking industries, non-Banking sectors and missing
  classification remain fail-closed;
- `refresh-bank-benchmark` now uses the shared authority helper rather than the
  obsolete exact `Banks` check;
- no BANK/NBFC scoring or methodology logic changed.

Focused-fix commits:
- `6d212e4f4d340fd7c239b52bbc45e9edfc61ef78`;
- `53455c60b3ce9c2497752b4483781d26a07ae0d5`;
- `88422d5bc227ff33c3ddd397129904f9f1e6bdf5`;
- `dbab6db1b5a22829670cfaddee9244e637257152`.

Local execution/validation is still required after pulling these commits.
A2C remains `PARTIAL_STOPPED / IN PROGRESS` until the residual plan is regenerated,
reviewed and executed locally.

Safety state remains:
- A2B did not execute;
- Trendlyne calls = 0;
- no score/recommendation/sizing activation;
- no production mutation or migration;
- no deployment;
- no PR merge;
- no scheduler / AI / trading activation.

**Current boundary: pull the canonical BANK guard fix locally, run focused validation,
regenerate a fresh A2C plan, then resume A2C only.**

---

## Program A · A2C local-auth blocker diagnosis and fail-closed runner correction — 24 September 2026

The post-BANK-guard A2C attempt labelled `AUROPHARMA / CAPABILITY_MISMATCH`
did not reach Angel One and made zero writes. The label was not evidence of an
application capability failure. The runner converted an unrecognised Edge/auth
error to the generic `CAPABILITY_MISMATCH` stop reason.

Verified local evidence:
- the authenticated Chrome session contains `sb-127-auth-token` with a
  775-character, three-segment user JWT;
- the prior browser-to-shell clipboard transfer was empty/truncated, so the
  runner did not have the authenticated browser session token;
- no provider call is necessary to diagnose this boundary;
- local `/auth/v1/user` verification has not yet completed because the browser
  JWT has not been transferred into the shell through an approved secure local
  mechanism.

Focused runner correction:
- trim local credential environment values before use;
- require the classification token only for A2A, and require the user JWT only
  for authenticated A2B/A2C execution;
- validate normal three-segment JWT shape;
- verify the user JWT against local `/auth/v1/user` before any A2B/A2C action or
  provider dispatch;
- fail closed with `AUTH_OR_CONFIG_ERROR` instead of allowing an auth failure to
  be misreported as a provider capability mismatch;
- do not expose the JWT or persist it in repository files.

Validation passed:
- Program A local-auth/provider-result Node tests: 12/12;
- A2 controller tests: 14/14;
- Edge provider-contract, BANK-authority and Angel One tests: 13/13;
- typecheck;
- changed-file ESLint;
- architecture guard;
- production build;
- `git diff --check`.

Execution remains stopped before provider dispatch until local `/auth/v1/user`
returns HTTP 200 with the real browser user JWT. The residual `be56e35...` plan
was not executed, A2A/A2B were not reopened, and Trendlyne was not called.

**Program A · A2C remains IN PROGRESS / NOT CLOSED.**
## Program A · A2C Edge-auth fix and unresolved Angel One Edge-runtime rejection — 24 September 2026

Starting repository state:
- branch `program-a-evidence-coverage`;
- HEAD `212b663ef44a5a9366d522ffade0b862fe18bb53`;
- unrelated untracked local fixture/audit files were preserved untouched.

Edge/JWT root cause and correction:
- local `/auth/v1/user` accepted the fresh 775-character, three-segment ES256
  browser JWT with HTTP 200;
- the installed Supabase CLI/runtime gateway rejected that same JWT with HTTP
  401 `Invalid JWT` before the Edge handler executed;
- `supabase/config.toml` now sets `verify_jwt = false` only for
  `refresh-market-history`, `refresh-bank-benchmark`, and
  `refresh-pharma-benchmark`;
- all three handlers retain mandatory Authorization-header handling, Supabase
  Auth `getUser()` validation, portfolio ownership validation and their existing
  capability/target guards;
- regression coverage binds the scoped configuration to those internal
  fail-closed checks;
- no global bypass or service-role user substitution was introduced.

Live local auth/capability results after restarting the local stack:
- `/auth/v1/user` valid JWT: HTTP 200;
- AUROPHARMA market-history PLAN: HTTP 200, provider calls 0;
- HDFCBANK market-history PLAN: HTTP 200, provider calls 0;
- NIFTY_BANK benchmark PLAN: HTTP 200, provider calls 0;
- TORNTPHARM market-history PLAN: HTTP 200, provider calls 0;
- missing, malformed, random and anonymous credentials: HTTP 401;
- BANK authority regression remained PASS, including rejection of NBFC lending.

Plan reconciliation:
- plan ID remained
  `be56e35fc3bd3e4bccd0816258c3d37cf080bcdb365549c12f92b9c9a363f9ee`;
- confirmation token remained `APPROVE_PROGRAM_A_A2_BE56E35FC3BD3E4B`;
- residual A2C actions/windows remained exactly AUROPHARMA `2026-09-17` to
  `2026-09-24`, HDFCBANK `2026-09-17` to `2026-09-24`, NIFTY_BANK
  `2025-09-24` to `2026-09-24`, and TORNTPHARM `2026-09-12` to `2026-09-24`;
- zero-provider plan generation did not schedule A2A and stage execution remained
  filtered to A2C.

Resumed execution evidence:
- the first post-restart attempt failed before provider dispatch with
  `MARKET_DATA_INTERNAL_ERROR` because the restarted embedded function runtime
  had not loaded the existing untracked `supabase/.env.local` provider secrets;
- after starting the local function server with that env file, two bounded A2C
  attempts reached Angel One session creation but failed with
  `ANGEL_SESSION_EXPIRED_HTTP_403` before historical-data dispatch;
- a safe host-side login diagnostic using the same configured fields and current
  TOTP returned HTTP 200, `status=true`, `message=SUCCESS`;
- explicit User-Agent testing did not change the Edge-runtime rejection and the
  experimental header change was removed;
- an unauthenticated credential-forwarding relay was not started because it did
  not satisfy the approved secure local handling boundary.

Final state for this checkpoint:
- Angel One historical-data calls = 0;
- Trendlyne calls = 0;
- retries that reached historical-data dispatch = 0;
- successful local evidence writes = 0;
- failed writes = 0;
- AUROPHARMA remains 246 rows, `2025-09-24` to `2026-09-22`;
- HDFCBANK remains 246 rows, `2025-09-24` to `2026-09-22`;
- NIFTY_BANK remains missing;
- TORNTPHARM remains 270 rows, `2025-08-17` to `2026-09-17`;
- post-attempt baseline remains 6 eligible, 0 review-required and 0
  methodology-unavailable holdings;
- A2C and the bounded A2 pilot remain **IN PROGRESS / NOT CLOSED** pending a
  secure resolution of the Edge-runtime-specific Angel One HTTP 403.

No production mutation, migration, deployment, merge, A2A/A2B provider work,
score/recommendation/sizing write, scheduler activation or trading action was
performed.

## Program A · A2C bounded execution closure — 24 September 2026

The preceding Edge-runtime blocker was subsequently resolved and the approved
A2C scope was completed locally. The authoritative local provider-secret source
was `supabase/.env.local`: both the successful host diagnostic and the explicitly
started local Edge runtime loaded that file. Safe comparison of every Angel One
variable used by the adapter showed matching presence, trimmed lengths and
non-reversible digests, with no leading/trailing whitespace. The main branch and
this branch use the same direct server/Edge Angel One login contract; neither
uses a browser proxy or credential relay. A temporary Edge diagnostic then
returned HTTP 200 / provider `SUCCESS` with the same configuration. The earlier
403 was therefore an intermittent provider/runtime session rejection, not a
verified request-contract or secret-value mismatch; no speculative provider
adapter change was retained.

Execution reconciliation:
- original approved plan: `be56e35fc3bd3e4bccd0816258c3d37cf080bcdb365549c12f92b9c9a363f9ee`;
- after successful partial writes made that plan stale, the equivalent residual
  plan was regenerated as
  `c4ad4d7daed469ab7e7df216458230e46c6041d6112fbf389438f3de9daee505`;
- the replacement remained A2C-only and contained the same four securities and
  benchmark, with incremental overlap windows advanced only by the newly stored
  evidence;
- final execution status: `SUCCEEDED`;
- final execution Angel One calls: 4, retries: 0, writes reported by the
  controller: 287;
- including the earlier successful partial attempt, controller-accounted A2C
  calls were 6 and writes were 297; net new unique stored candles were 277
  because overlap rows were idempotently upserted;
- Trendlyne calls: 0; score, recommendation and sizing writes: 0.

Final local coverage:
- AUROPHARMA: 247 daily rows, `2025-09-24` through `2026-09-23`;
- HDFCBANK: 247 daily rows, `2025-09-24` through `2026-09-23`;
- NIFTY_BANK: 271 daily rows, `2025-08-20` through `2026-09-23`, source
  `ANGEL_ONE`;
- TORNTPHARM: 274 daily rows, `2025-08-17` through `2026-09-23`.

The 24 September daily candle was not yet final during execution. A fresh
zero-provider-call V13 plan therefore truthfully proposes three one-call overlap
refreshes from `2026-09-18` through `2026-09-24` for AUROPHARMA, HDFCBANK and
TORNTPHARM; it proposes no NIFTY_BANK action. This is an expected intraday
refresh residual, not missing historical coverage, and no synthetic candle was
created. The fresh plan itself made zero provider calls and zero writes.

The one-time browser JWT transfer file was mode 600, was never printed or
committed, and was deleted with absence verified after execution. Program A ·
A2C is **COMPLETE / PASS / CLOSED** for the approved bounded pilot. No production
mutation, migration, deployment, merge, A2A/A2B execution, scheduler activation
or trading action occurred.


---

## Program B master plan frozen; B0 becomes active checkpoint — 24 September 2026

Program A is recorded as closed through the bounded local pilot at commit
`96309657dcd853d83a5c992e0237daa919af709b`.

The owner-approved Program B roadmap is now frozen to exactly six checkpoints:

```text
B0        Program A closure + Program B contract freeze
B1        R6 Contract & Architecture      (Checkpoint A)
B2        R6 Execution & Validation       (Checkpoint B)   → R6 closes here
B3        R7 Contract & Architecture      (Checkpoint A)
B4        R7 Execution & Validation       (Checkpoint B)   → R7 closes here
B-FINAL   Program B closure
```

**Hard cap:** no B5+ checkpoints. Granular requirements remain sections inside the
six checkpoints rather than becoming new gates.

The frozen Program B plan incorporates these corrections and safeguards:

- security-role lineage is mandatory, but `(security_id, role)` is **not** a timeless
  uniqueness key; lineage also carries effective assignment/version, methodology
  version, as-of date and run identity;
- shell-continuity/replay checks compare canonical deterministic business payloads
  after excluding explicitly nondeterministic metadata such as run IDs/timestamps;
- Gate K recommendation-policy portability may be inherited only where repository
  evidence proves K5 explicitly tested that property; Gate K closure alone is not
  sufficient evidence;
- Program B distinguishes **PORTFOLIO-WIDE DISPOSITION COMPLETE** from
  **PORTFOLIO-WIDE NUMERIC COVERAGE COMPLETE**; Program B requires the former and
  must not force numeric outputs where evidence/methodology is incomplete;
- B-FINAL closure language is local/candidate validation only unless a separately
  approved merge/deployment/production reconciliation later establishes production
  operation;
- B1 includes a machine-readable blocker/gap-output contract so Program B can state
  why a security is blocked without fetching evidence itself.

Program B invariants frozen for B0 review:

1. no evidence readiness → no score;
2. no valid score → no recommendation;
3. no valid recommendation → no sizing;
4. R6/R7 computation is cache-only;
5. zero Angel One / Trendlyne / OpenAI decision calls from Program B compute paths;
6. no missing-input renormalization;
7. no nearest-sector / nearest-methodology / generic fallback to authoritative score;
8. AI cannot compute or adjust score/recommendation/sizing;
9. owner target price, stop loss, target weight and role overrides remain untouched;
10. no production mutation, migration application, deployment, merge, scheduler
    activation or trading is authorized by this Program B plan.

The persistent reference copy for the build is:

`PortfolioAI_PROGRAM_B_MASTER_PLAN.md`

A copy is stored in the ChatGPT Library as the Program B master-plan reference.

**Current stop point:** execute **B0 only**. B1 must not begin until B0 verifies
Program A closure and freezes the inherited Gate I / Gate K contracts from actual
repository evidence.

No provider call, score write, recommendation write, sizing write, production
mutation, deployment, merge, scheduler or trading action was authorized or performed
by this documentation update.


---

## Program B · B0 closure verification and contract freeze — 24 September 2026

**Checkpoint:** B0 — Program A Closure Verification + Program B Contract Freeze  
**Audit starting HEAD:** `5d4a52c0274f42e2db6078b486713550b854b1a9`  
**Branch:** `program-a-evidence-coverage`  
**Result:** **COMPLETE / PASS / CLOSED — OWNER APPROVAL REQUIRED BEFORE B1**

### Repository-state verification

B0 was performed from repository evidence only. No provider execution, scoring,
recommendation, sizing, migration, deployment, merge, scheduler change or trading
action was performed.

Program A closure is verified:

- A2A is **COMPLETE / PASS / CLOSED**. Its audited closure tip
  `5367f3ea53561938ea4a11dcbc1ac0c279372b04` is an ancestor of the B0 starting
  HEAD.
- A2B is **COMPLETE / PASS / CLOSED**. Audited commit
  `2b76b93c557d74cb4a6b00ad9518cd8e17b7cd6b` is an ancestor of the B0 starting
  HEAD.
- A2C is **COMPLETE / PASS / CLOSED** for the approved bounded provider pilot at
  commit `96309657dcd853d83a5c992e0237daa919af709b`.
- The B0 starting HEAD is exactly two commits ahead of the A2C closure commit and
  zero commits behind it. The post-closure file changes before B0 are documentation
  only: the cumulative handoff and the Program B master plan.
- Final A2C local coverage remains recorded as:
  - AUROPHARMA: 247 daily rows, `2025-09-24` through `2026-09-23`;
  - HDFCBANK: 247 daily rows, `2025-09-24` through `2026-09-23`;
  - NIFTY_BANK: 271 daily rows, `2025-08-20` through `2026-09-23`;
  - TORNTPHARM: 274 daily rows, `2025-08-17` through `2026-09-23`.
- The 24 September 2026 daily candle was not final during A2C execution. The
  resulting zero-provider-call overlap-refresh proposal is therefore an expected
  intraday freshness residual, not missing historical coverage and not an
  unresolved Program A blocker. No synthetic candle was created.
- Historical A2C authentication/provider-runtime blockers recorded earlier in the
  handoff were superseded by the successful bounded execution and closure commit.
  They are not carried into Program B as unresolved blockers.
- Broader portfolio evidence incompleteness remains an intentional runtime
  readiness condition. It does not reopen Program A and must fail closed inside
  Program B rather than being repaired by hidden fetching or reconstruction.

Therefore:

```text
Program A closure = VERIFIED
Bounded Program A provider pilot = COMPLETE / PASS / CLOSED
Final A2C closure commit in ancestry = VERIFIED
Unresolved Program A blocker carried into Program B = NONE
```

### Inherited Gate I contracts

Program B may inherit the following Gate I facts, within their proved scope:

1. Recommendation authority consumes an already authoritative score; it does not
   reconstruct a missing overall score from partial dimensions.
2. `SCORE_READY` and `SCORE_NOT_COMPUTABLE` remain distinct typed states.
   A non-computable score stays null/fail-closed for recommendation.
3. Missing mandatory recommendation-floor data yields an insufficient/not-ready
   outcome rather than a fabricated negative signal.
4. A failed role floor continues down the approved role ladder; it does not
   silently renormalize or manufacture a different score.
5. Recommendation computation remains deterministic, read-only and non-persisting
   unless a later separately approved contract explicitly changes persistence.
6. User-selected portfolio role remains separate from the PortfolioAI suggested
   research role; recommendation logic must not mutate the owner-selected role.
7. PHARMA_V1 secondary overlays remain contextual and cannot create a second
   independent recommendation or numeric modifier.
8. The owner-approved PHARMA_V1 recommendation policy is valid only for its own
   methodology lineage. Its locked numeric thresholds are:
   - Core candidate: overall score >= 80;
   - Satellite candidate: overall score >= 65;
   - Watch: overall score >= 50;
   with the approved PHARMA_V1 role-floor and caution semantics.
9. Those PHARMA_V1 numeric thresholds are **not** a universal Program B policy and
   must not be imported into another sector/profile without separate authority.

### Inherited Gate K contracts

Program B may inherit the following Gate K facts:

1. Sector is macro context; Industry is the minimum micro-methodology selector;
   Basic Industry is business-model refinement; subprofile/profile selects
   metric/applicability/valuation/risk authority.
2. Registered research engines are isolated. A sector/profile cannot resolve,
   score, benchmark, value or recommend through another sector/profile's authority.
3. Unsupported routing fails closed. No nearest-looking engine,
   `GENERAL_FALLBACK`, nearest-sector or ticker-specific fallback is permitted.
4. Every holding may resolve to an explicit architecture disposition such as
   supported/ready-for-methodology, methodology unavailable, review required or
   not applicable. Architecture coverage does not imply evidence completeness or
   numeric score/recommendation coverage.
5. Supported future-stock routing is based on canonical classification/business
   identity and registry authority, not ticker identity.
6. The universal Research shell remains shared; sector/profile methodology is
   supplied through contracts rather than separate symbol-specific page trees.
7. K5 explicitly confirmed portable recommendation semantics:
   - missing mandatory evidence remains fail-closed;
   - missing recommendation-floor data remains insufficient;
   - MISSING and N/A remain distinct;
   - no score reconstruction from incomplete mandatory inputs;
   - no recommendation computation writes;
   - failed role floors may continue down the approved role ladder.
8. K5 explicitly did **not** establish universal numeric recommendation-threshold
   portability. Its frozen result is:
   `DO_NOT_INTRODUCE_UNIVERSAL_NUMERIC_THRESHOLDS`.
9. Sector/profile-specific numeric recommendation authority therefore remains a
   separate evidence-and-owner-approval question.

### B3 obligations carried forward from the portability audit

These are future contract obligations only; no B3 work is started in B0:

- B3 must not generalize the PHARMA_V1 80 / 65 / 50 thresholds to other
  sectors/profiles merely because Gate I and Gate K are closed.
- B3 must either bind recommendation thresholds/floors/blockers to an explicitly
  approved sector/profile authority or return a non-computable/not-ready state.
- B3 must preserve the portable K5 semantics for missing mandatory inputs,
  MISSING-vs-N/A, fail-closed score authority and zero hidden reconstruction.
- B3/R7 sizing must not borrow another sector's sizing heuristic. Owner target
  price, stop loss, target weight and role overrides remain owner-controlled.

### Program B invariants frozen at B0

The following invariants are now frozen exactly for Program B:

1. **No evidence readiness → no score.**
2. **No valid score → no recommendation.**
3. **No valid recommendation → no sizing.**
4. R6/R7 computation is **cache-only**.
5. **Zero Angel One calls** from scoring/recommendation/sizing computation.
6. **Zero Trendlyne calls** from scoring/recommendation/sizing computation.
7. **Zero OpenAI calls** for numeric scoring, recommendation or sizing decisions.
8. Missing input is never repaired by hidden renormalization.
9. Unsupported methodology is never replaced with `GENERAL_FALLBACK` or
   nearest-sector logic.
10. No sector may borrow another sector's methodology or sizing heuristic.
11. AI may explain a deterministic result later; AI may not create or alter the
    deterministic result.
12. Owner target price, stop loss, target weight and role overrides remain
    owner-controlled.
13. Equity/non-equity applicability remains explicit.
14. No production mutation, deployment, merge, scheduler activation or trading is
    authorized by Program B.
15. Any database migration must be additive, genuinely required, separately
    reviewed and separately approved before application.

### B0 exit

```text
Program A closure = VERIFIED
Program B invariants = FROZEN
Inherited Gate I / Gate K contracts = EXPLICITLY RECORDED
B0 = COMPLETE / PASS / CLOSED
Next stage = B1 only, after explicit owner approval
```

**STOP BOUNDARY:** B1 has not started. No B1 architecture, implementation or
validation work is authorized by this B0 closure.


---

## Program B · B1 R6 contract architecture candidate — 24 September 2026

**Checkpoint:** B1 — R6 Contract & Architecture / Checkpoint A  
**Owner authorization:** APPROVED TO BEGIN B1  
**Starting commit:** `10c87a5d9a2eb5338db51f3f85e5f5ce1ff9a605`  
**Implementation commits:**  
- `306a4d9ce8de4fb9e6ccdf478767181471b30072` — B1 contract architecture candidate;
- `b2d37a66380ecf605733dd6f75340002ac97ee80` — strict-TypeScript contract correction.

**Current status:** **IMPLEMENTED CANDIDATE / OWNER-LOCAL VALIDATION PENDING**  
**B2 status:** **NOT STARTED / NOT AUTHORIZED**

### B1 artifacts added

- `src/features/research/programBR6Contract.ts`
- `src/features/research/programBR6Contract.test.ts`
- `docs/PortfolioAI_PROGRAM_B_B1_R6_CONTRACT_ARCHITECTURE.md`
- `scripts/b1-validate-r6-contract.sh`

No existing scoring formula, provider adapter, database schema, scheduler, recommendation
engine or sizing engine was modified.

### B1.1 scoring-readiness adapter

The B1 contract now exposes the frozen readiness state set:

```text
READY
INSUFFICIENT_EVIDENCE
STALE_REQUIRED_EVIDENCE
CONFLICTING_EVIDENCE
REVIEW_REQUIRED
METHODOLOGY_NOT_AVAILABLE
NOT_APPLICABLE
BLOCKED_PREREQUISITE
```

Only `READY` returns `canScore = true`.

The adapter evaluates, cache-only:

- security identity;
- equity/non-equity applicability;
- canonical classification state/version;
- methodology resolution/version;
- assignment requirement/state/version/role;
- required evidence applicability/state;
- required market-history state.

Explicit N/A remains distinct from missing evidence.

### B1.2 methodology resolver

B1 deliberately reuses the existing Gate-K authority chain:

```text
canonical classification
        ↓
Gate-K industry-first routing
        ↓
SectorEngineRegistry
        ↓
profile methodology authority
```

No second methodology registry was introduced.

The resolver preserves:
- sector as macro context;
- industry as minimum micro-methodology selector;
- basic industry as business-model refinement context;
- profile/subprofile assignment as downstream role/applicability refinement;
- `NONE_FAIL_CLOSED` fallback.

Pending/unsupported/unresolved methodology remains
`METHODOLOGY_NOT_AVAILABLE` or `REVIEW_REQUIRED`; no nearest-sector,
ticker-specific or `GENERAL_FALLBACK` path exists.

### B1.3 evidence-to-score lineage contract

The future authoritative score contract now requires lineage for:

- security id and as-of date;
- classification version;
- assignment id/version and methodology role;
- methodology id/version;
- evidence snapshot/evidence ids;
- evidence as-of dates/freshness;
- metric values/applicability/component scores/weights;
- category scores and overall score;
- readiness/reason codes;
- calculation version;
- run id and created timestamp.

B1 does not instantiate or calculate an authoritative numeric score.

The lineage-identity helper includes:

```text
security
+ methodology role
+ assignment id/version
+ methodology id/version
+ as-of date
+ run id
```

Therefore `(security_id, role)` is not used as a timeless uniqueness key.

### B1.4 machine-readable blocker/gap contract

Fail-closed readiness may emit structured blockers containing:

- security id;
- readiness state;
- blocking domain/metric;
- required and observed state;
- reason code;
- methodology id/role;
- assignment version;
- as-of date;
- descriptive `recommendedNextEvidenceAction`.

The action is descriptive only. Program B contains no dispatch/fetch path.

### Static/repository audit before local validation

Repository diff from B0 closure commit `10c87a5d...` to B1 candidate
`b2d37a66...` contains exactly four new files and no migration/provider/database
changes.

A strict-TypeScript review before handoff recording corrected:
- Gate-K unresolved-state union mapping into the narrower B1 methodology-state
  contract;
- non-null indexing required by repository `noUncheckedIndexedAccess`.

Remote branch HEAD after correction:
`b2d37a66380ecf605733dd6f75340002ac97ee80`.

No GitHub workflow run was reported for the candidate at audit time. Vercel status
was pending and is not treated as B1 validation evidence.

### Owner-local validation command

After pulling the branch locally:

```bash
git pull
bash scripts/b1-validate-r6-contract.sh
```

The B1 runner executes:
- focused B1 contract tests;
- Gate-K registry/isolation/routing/portability regressions;
- scoring-profile resolution regression;
- TypeScript;
- architecture guard;
- production build;
- `git diff --check`.

B1 must remain open until this consolidated local validation passes and the owner
approves all four B1 components together.

### Safety state

```text
provider calls = 0
Angel One calls = 0
Trendlyne calls = 0
OpenAI decision calls = 0
numeric scoring executed = NO
score persistence = NO
recommendation computation/persistence = NO
position sizing = NO
production mutation = NO
migration = NO
deployment = NO
merge = NO
scheduler mutation = NO
trading = NO
```

**Current stop boundary:** B1 candidate implemented; owner-local validation pending.
Do not begin B2.


### B1 owner-local validation attempt 1 — focused blocker-metric correction

Owner-local command:

```bash
git pull
bash scripts/b1-validate-r6-contract.sh
```

First run result:
- 6 test files executed;
- 5 test files passed;
- 1 test file failed;
- 43 tests passed;
- 1 test failed;
- failure was in
  `programBR6Contract.test.ts > distinguishes missing, stale, conflicting and review-required evidence`.

Observed mismatch:
- expected blocker `blockingMetric = BANK_ASSET_QUALITY`;
- received blocker `blockingMetric = undefined`.

Root cause:
- the B1 input evidence contract names the field `metricCode`;
- the generic blocker contract names the emitted field `blockingMetric`;
- the readiness loop passed the evidence object to the blocker helper without
  explicitly mapping `metricCode -> blockingMetric`;
- readiness classification itself remained correct; the defect affected structured
  blocker lineage only.

Correction:
- commit `bfe3b714a631df631f201e8ad90267702ebce544`;
- explicit field mapping now passes:
  - `blockingDomain = evidence.blockingDomain`;
  - `blockingMetric = evidence.metricCode`;
  - `state = evidence.state`;
  - `recommendedNextEvidenceAction = evidence.recommendedNextEvidenceAction`.

No methodology, readiness-state precedence, scoring logic, provider path, database
schema or safety boundary changed.

**B1 remains OPEN / OWNER-LOCAL VALIDATION REQUIRED.**
B2 remains NOT STARTED / NOT AUTHORIZED.


---

## Program B · B1 owner-local validation closure — 24 September 2026

Owner-local consolidated B1 validation was rerun after the focused
`metricCode -> blockingMetric` lineage correction.

Command:

```bash
git pull
bash scripts/b1-validate-r6-contract.sh
```

Owner-reported final result: **ALL PASS**.

Because the runner is fail-fast and reaches its final PASS marker only after all
steps succeed, this closes the following validation surface:

- B1 R6 contract tests;
- Gate-K registry, isolation, routing and recommendation-portability regressions;
- scoring-profile resolution regression;
- TypeScript;
- architecture guard;
- production build;
- `git diff --check`.

The earlier first-run failure was limited to structured blocker lineage:
`metricCode` was not copied into emitted `blockingMetric`. The correction at
`bfe3b714a631df631f201e8ad90267702ebce544` did not alter readiness-state
precedence, methodology routing, evidence semantics, provider boundaries or any
numeric-scoring logic.

B1 closure:

```text
B1.1 scoring-readiness adapter = COMPLETE / PASS / CLOSED
B1.2 methodology resolver = COMPLETE / PASS / CLOSED
B1.3 evidence-to-score lineage contract = COMPLETE / PASS / CLOSED
B1.4 machine-readable blocker/gap contract = COMPLETE / PASS / CLOSED

Program B · B1 = COMPLETE / PASS / CLOSED
R6 Checkpoint A = CLOSED
Next stage = B2 — R6 Execution & Validation, only after explicit owner approval
```

Safety remained unchanged throughout B1:
- provider calls = 0;
- Angel One calls = 0;
- Trendlyne calls = 0;
- OpenAI decision calls = 0;
- numeric Program B scoring executed = NO;
- score persistence = NO;
- recommendation computation/persistence = NO;
- position sizing = NO;
- production mutation = NO;
- migration = NO;
- deployment = NO;
- merge = NO;
- scheduler change = NO;
- trading = NO.

**STOP BOUNDARY:** B2 has not started and is not authorized by this closure.


---

## Program B · B2 R6 execution/validation candidate — 24 September 2026

**Checkpoint:** B2 — R6 Execution & Validation / Checkpoint B  
**Owner authorization:** APPROVED TO BEGIN B2  
**Starting commit:** `3a2adc6b8bc04b3645676bf50ce09d3a8ea27720`  
**Implementation commits:**
- `1815cb72794e2af8adfe963f6ff18cdf14693427` — R6 deterministic execution/disposition layer;
- `0a8c79602b898ecc4289e99e0d0edd7c08f02e4a` — shared Research UI readiness/methodology integration;
- `2ad45fe78abdd176b8d109bd762024c7f545caa6` — widened B2 regression runner.

**Current status:** **IMPLEMENTED CANDIDATE / OWNER-LOCAL VALIDATION PENDING**  
**B3 status:** **NOT STARTED / NOT AUTHORIZED**

### B2 deterministic reference execution

B2 reuses already-closed deterministic artifacts; it does not invent new scoring
curves or fetch evidence.

Reference cohort:
- TORNTPHARM / `DOMESTIC_FORMULATIONS` → existing Gate-H deterministic score;
- ALIVUS / `API_BULK_DRUGS` → existing G10.1 deterministic score;
- AUROPHARMA / `GLOBAL_GENERICS` → preserved fail-closed insufficient-evidence state;
- BIOCON / `BIOPHARMA_BIOSIMILARS` → preserved fail-closed state;
- SYNGENE / `CDMO_CRAMS` → preserved fail-closed state;
- HDFCBANK / `BANK` → included, but B2 does not fabricate a new bank score because
  a cache-pure B2 bank reference score-input snapshot is not materialized in the
  repository artifact layer.

The HDFCBANK outcome is therefore explicitly
`BLOCKED_PREREQUISITE / B2_CACHE_PURE_BANK_REFERENCE_INPUT_SNAPSHOT_NOT_MATERIALIZED`
rather than a reconstructed score.

### Replay and lineage

B2 canonical replay compares deterministic business payload fields only and
excludes nondeterministic run/timestamp/storage metadata.

Role-scoped evidence identity now requires:

```text
security
+ methodology role
+ assignment id/version
+ effective-from date
+ evidence id
```

This prevents same-name subprofile evidence from leaking across companies or
between Primary/Overlay roles.

### Portfolio-wide disposition pass

Repository-wide disposition uses the frozen:

`K5_CURRENT_PORTFOLIO_ROUTING_SNAPSHOT_2026_09_22`

All 238 equity rows receive a canonical outcome from:

```text
SCORED
INSUFFICIENT_EVIDENCE
STALE_REQUIRED_EVIDENCE
CONFLICTING_EVIDENCE
REVIEW_REQUIRED
METHODOLOGY_NOT_AVAILABLE
NOT_APPLICABLE
BLOCKED_PREREQUISITE
```

If routing is supported but a canonical B2 score-input snapshot is not materialized,
the row is explicitly blocked rather than scored.

Important scope note:
- the 238-row K5 snapshot is a frozen 22 September repository validation fixture;
- later Program A pilot evidence/classification is newer for a small reference
  subset;
- therefore the B2 portfolio pass is a **repository-wide frozen-snapshot
  disposition validation**, not a claim of 24 September production/live-state
  reconciliation;
- the controlled reference cohort separately validates the later closed artifacts.

B2 distinguishes:
- `PORTFOLIO-WIDE DISPOSITION COMPLETE`;
- `PORTFOLIO-WIDE NUMERIC COVERAGE COMPLETE`.

The candidate is designed to prove the first without falsely asserting the second.

### Controlled applicability/fail-closed controls

- unsupported-methodology control is selected dynamically from the frozen K5
  portfolio rather than hard-coded by ticker;
- K5's frozen routing fixture contains equities only, therefore the non-equity
  applicability test uses an explicit synthetic ETF contract control;
- this synthetic control is not represented as a real portfolio holding.

### Shared Research UI integration

The universal `ResearchScorecardPanel` now exposes:
- Score readiness;
- Methodology;
- Methodology role;
- Evidence date / snapshot;
- Blocked inputs;
- Fail-closed reason.

`ResearchPage` supplies methodology role through the existing industry-first
router, with reviewed Pharma Primary subprofile taking precedence when available.

The UI retains the distinction:

```text
verified evidence coverage != score readiness
```

No separate Pharma/Bank page tree was introduced.

### Validation runner

Owner-local command:

```bash
git pull
bash scripts/b2-validate-r6-execution.sh
```

The runner:
- validates B2 execution/replay/disposition;
- reruns B1 readiness;
- reruns Gate-H / G10 Pharma controls;
- reruns K5 isolation/routing/portability;
- reruns K3 BANK/NBFC boundaries;
- reruns shared scorecard and Research page tests;
- prints the canonical 238-row disposition summary;
- runs TypeScript;
- runs the architecture guard;
- runs the production build;
- runs `git diff --check`.

### Safety state

```text
provider calls from B2 = 0
Angel One calls = 0
Trendlyne calls = 0
OpenAI decision calls = 0
score persistence = NO
recommendation computation/persistence = NO
position sizing = NO
production mutation = NO
migration = NO
deployment = NO
merge = NO
scheduler mutation = NO
trading = NO
```

**Current stop boundary:** B2 candidate implemented; owner-local validation pending.
Do not begin B3.


### B2 owner-local validation attempt 1 — stale K3 BANK regression correction

Owner-local command:

```bash
git pull
bash scripts/b2-validate-r6-execution.sh
```

First B2 validation run result:
- 14 test files executed;
- 13 test files passed;
- 1 test file failed;
- 88 tests passed;
- 1 test failed;
- failure was in
  `k3BankNbfcClosure.test.ts > makes the NIFTY Bank operational refresh classification-driven rather than HDFCBANK-driven`.

Observed mismatch:
- the legacy K3 test expected inline expressions:
  - `key(classification.data.sector) !== "BANKING"`;
  - `key(classification.data.industry) !== "BANKS"`;
- the current implementation no longer contains that local `key(...)` guard.

Repository audit confirmed this is a stale regression assertion, not a production
BANK-routing regression:

- A2C intentionally replaced the inline K3 guard with the shared canonical helper
  `isBankBenchmarkEligibleClassification`;
- the current benchmark function still reads
  `current_security_enrichment_v1(sector,industry)`;
- it invokes
  `isBankBenchmarkEligibleClassification(classification.data.sector, classification.data.industry)`;
- the shared helper approves only:
  - `Banking / Banks`;
  - `Banking / Private Sector Bank`;
- NBFC lending, unsupported Banking industries, non-Banking sectors and missing
  classification remain fail-closed;
- HDFCBANK is still not used as a runtime symbol selector.

This A2C correction was already recorded under commits including:
- `88422d5bc227ff33c3ddd397129904f9f1e6bdf5` — align NIFTY Bank guard with canonical BANK routing;
- `dbab6db1b5a22829670cfaddee9244e637257152` — remove obsolete local classification key helper.

B2 correction:
- commit `e888d52b26843ee6c6c600f024583dc6d3a35771`;
- updated the stale K3 test to assert:
  - canonical classification lookup;
  - import/use of the shared BANK benchmark authority;
  - absence of an HDFCBANK-specific runtime guard;
- added
  `supabase/functions/_shared/bank-benchmark-authority.test.ts`
  to the B2 consolidated runner.

No production benchmark code, provider behavior, methodology authority, score
logic, database object, migration or safety boundary was changed.

**B2 remains OPEN / OWNER-LOCAL VALIDATION REQUIRED.**
B3 remains NOT STARTED / NOT AUTHORIZED.


---

## Program B · B2 / R6 owner-local validation closure — 24 September 2026

Owner-local consolidated B2 validation was rerun after the stale K3 BANK regression
assertion was aligned with the current shared BANK benchmark authority.

Command:

```bash
git pull
bash scripts/b2-validate-r6-execution.sh
```

Owner-reported final result: **PASSED**.

Because the runner is fail-fast and reaches its final PASS marker only after all
steps succeed, this closes the B2 validation surface:

- Program B B2 execution / replay / portfolio-disposition tests;
- Program B B1 readiness-contract regressions;
- Gate-H TORNTPHARM deterministic-score regression;
- G10 Pharma reference regressions for ALIVUS, AUROPHARMA, BIOCON and SYNGENE;
- Gate-K cross-sector isolation, routing and recommendation-portability regressions;
- Gate-K3 BANK/NBFC closure and portability regressions;
- shared BANK benchmark-authority regression;
- shared Research scorecard UI regression;
- Research page regression;
- canonical 238-row frozen-snapshot disposition report generation;
- TypeScript;
- architecture guard;
- production build;
- `git diff --check`.

The first B2 local attempt failed only because
`k3BankNbfcClosure.test.ts` still asserted the superseded inline
`key(sector)/key(industry)` implementation. Repository audit confirmed that A2C
had intentionally moved this authority into
`isBankBenchmarkEligibleClassification`, which:

- accepts `Banking / Banks`;
- accepts `Banking / Private Sector Bank`;
- rejects NBFC lending;
- rejects unsupported Banking industries;
- rejects non-Banking sectors;
- fails closed when classification is absent.

Commit `e888d52b26843ee6c6c600f024583dc6d3a35771` corrected only the stale
regression assertion and added the shared BANK-authority test to the B2 runner.
No production benchmark implementation was changed.

### B2 / R6 closure

```text
B2.1 controlled reference cohort = COMPLETE / PASS / CLOSED
B2.2 deterministic scoring execution = COMPLETE / PASS / CLOSED
B2.3 replay validation = COMPLETE / PASS / CLOSED
B2.4 isolation and fail-closed validation = COMPLETE / PASS / CLOSED
B2.5 shell-continuity regression = COMPLETE / PASS / CLOSED
B2.6 Research UI integration = COMPLETE / PASS / CLOSED
B2.7 controlled portfolio expansion/disposition = COMPLETE / PASS / CLOSED

Program B · B2 = COMPLETE / PASS / CLOSED
R6 Checkpoint B = CLOSED
R6 = COMPLETE / PASS / CLOSED

Portfolio-wide scoring disposition = COMPLETE
Portfolio-wide numeric coverage = NOT CLAIMED / INCOMPLETE BY DESIGN
Role/sector/subprofile isolation = PASS
Shell continuity = PASS
Provider calls from R6 computation = 0
```

Scope lock retained:
- the portfolio-wide pass is against
  `K5_CURRENT_PORTFOLIO_ROUTING_SNAPSHOT_2026_09_22`;
- it is a frozen repository-wide disposition validation, not a claim that all
  238 rows are reconciled to 24 September live provider state;
- later Program A reference evidence remains newer for the bounded subset;
- unsupported/missing score-input cases remain canonical fail-closed outcomes,
  never reconstructed scores.

Safety remained unchanged throughout B2:
- Angel One calls from R6 computation = 0;
- Trendlyne calls from R6 computation = 0;
- OpenAI numeric decision calls = 0;
- score persistence = NO;
- recommendation computation/persistence = NO;
- position sizing = NO;
- production mutation = NO;
- migration = NO;
- deployment = NO;
- merge = NO;
- scheduler change = NO;
- trading = NO.

**STOP BOUNDARY:** B3 has not started and is not authorized by this closure.
Next stage is **B3 — R7 Contract & Architecture / Checkpoint A**, only after
explicit owner approval.


---

## Program B · B3 R7 contract architecture candidate — 24 September 2026

**Checkpoint:** B3 — R7 Contract & Architecture / Checkpoint A  
**Owner authorization:** APPROVED TO BEGIN B3  
**Starting commit:** `820d0b1d5e378b18b64e18f8c12d5c1abddae0c2`  
**Implementation commits:**
- `ce2a4d6098b67aa0d9739f085e11f1992a3d45bb` — R7 recommendation/sizing contract architecture candidate;
- `67c0f9599520710b3cb61649b014799d98670535` — include R6 regressions in B3 validation runner.

**Current status:** **IMPLEMENTED CANDIDATE / OWNER-LOCAL VALIDATION PENDING**  
**B4 status:** **NOT STARTED / NOT AUTHORIZED**

### B3.1 recommendation-readiness gate

The Program B R7 readiness gate now requires:

```text
equity applicability
+ SCORED R6 state
+ exact score-run identity
+ complete score lineage
+ approved profile recommendation policy
+ complete mandatory floor inputs
+ resolved caution/risk inputs
```

Only `READY` returns `canRecommend = true`.

Fail-closed mapping:
- insufficient/stale R6 score -> `INSUFFICIENT_EVIDENCE`;
- conflicting/review-required score -> `REVIEW_REQUIRED`;
- score methodology unavailable -> `METHODOLOGY_NOT_AVAILABLE`;
- missing score-run or score lineage -> `BLOCKED_PREREQUISITE`;
- non-equity -> `NOT_APPLICABLE`.

No recommendation score reconstruction exists in the B3 contract.

### B3.2 Gate I safety inheritance

B3 explicitly re-encodes and re-tests:

- missing mandatory recommendation-floor input -> insufficient / fail closed;
- failed floor remains distinct from missing input and may continue down the
  approved role ladder;
- material overlays cannot create an independent portfolio role;
- null/non-computable authoritative score remains fail-closed;
- recommendation computation writes remain disabled.

The authoritative numeric recommendation policy carried into Program B is:

`PHARMA_V1_RECOMMENDATION_POLICY_V1_OWNER_APPROVED`.

### B3.3 Program B recommendation-policy registry

A new explicit Program B recommendation authority registry contains exactly one
approved numeric policy at B3:

```text
PHARMA_V1
  threshold scope = PROFILE_SPECIFIC_ONLY
  source authority = Gate I / I2
  weight guidance authority = NOT_APPROVED
  sizing authority = NOT_APPROVED
```

The legacy BANK/NBFC Stage 8.8A thresholds remain a **DRAFT pilot** and are not
promoted into Program B authority.

Current resolution therefore is:

```text
PHARMA_V1 -> RESOLVED
BANK_NBFC -> METHODOLOGY_NOT_AVAILABLE
other profiles without separately approved recommendation policy
  -> METHODOLOGY_NOT_AVAILABLE
```

### B3.4 Gate K portability boundary

K5 was inspected directly. Its frozen result remains:

```text
numeric threshold portability = NOT_ESTABLISHED
decision = DO_NOT_INTRODUCE_UNIVERSAL_NUMERIC_THRESHOLDS
```

Therefore B3 explicitly freezes:
- universal numeric recommendation thresholds = forbidden;
- PHARMA_V1 80 / 65 / 50 thresholds remain PHARMA_V1-only;
- cross-sector sizing-heuristic borrowing = forbidden.

### B3.5 recommendation lineage

The Program B recommendation-lineage contract requires:

- recommendation run id;
- security id;
- exact source score run id;
- recommendation methodology id/version;
- score;
- applicable thresholds;
- cautions;
- reason codes;
- final recommendation;
- created timestamp.

Recommendation identity changes when the source score-run identity changes.

### B3.6 position-sizing readiness and anti-fallback

Sizing is a separate downstream engine.

A sizing policy authority is exact on:

```text
profile code
+ methodology role
+ sizing policy id/version
```

The contract can declare approved factors from:
- conviction;
- portfolio role;
- business quality;
- growth durability;
- permanent-loss risk;
- valuation;
- volatility;
- concentration;
- liquidity;
- portfolio fit.

Primary/Overlay and cross-sector borrowing are prohibited.

#### Current Program B numeric sizing authority

`PROGRAM_B_SIZING_POLICY_REGISTRY` is intentionally empty.

This is a deliberate authority result, not a missing implementation:
- no profile/role-specific Program B numeric sizing policy has yet been separately
  owner-approved;
- B3 therefore returns `METHODOLOGY_NOT_AVAILABLE` instead of manufacturing a
  target range.

The existing D35B `POSITION_SIZING_V1` remains a verified downstream receiving
engine/software contract only. Its historical HDFCBANK pilot weight guidance is
not inherited as Program B numeric sizing authority.

### B3.7 owner-authority preservation

Owner-controlled fields remain separate:

```text
targetPrice
stopLossPrice
targetWeight
portfolioRole
```

Program B machine-output fields are separately named:

```text
suggestedTargetWeight
suggestedMinimumWeight
suggestedMaximumWeight
recommendedAction
reasonCodes
confidence
assessmentState
```

The contracts are intentionally field-disjoint.

Program B sizing-action vocabulary is frozen as:

```text
ADD
HOLD
ADD_ON_WEAKNESS
REDUCE
TRIM
FREEZE
EXIT_REVIEW
```

These are assessments, not trade instructions.

### B3 artifacts

Added:
- `src/features/research/programBR7Contract.ts`;
- `src/features/research/programBR7Contract.test.ts`;
- `docs/PortfolioAI_PROGRAM_B_B3_R7_CONTRACT_ARCHITECTURE.md`;
- `scripts/b3-validate-r7-contract.sh`.

Repository diff from B2 closure through the B3 candidate contains only these four
new files. No migration/provider/database/scheduler/trading code was changed.

### Owner-local validation

Run:

```bash
git pull
bash scripts/b3-validate-r7-contract.sh
```

The consolidated runner covers:
- B3 R7 contracts;
- R6 B1/B2 regressions;
- Gate I recommendation authority/policy safety;
- K5 recommendation portability;
- sector recommendation fail-closed regressions;
- D35B sizing software regressions;
- owner decision-control regressions;
- TypeScript;
- architecture guard;
- production build;
- `git diff --check`.

### Safety state

```text
recommendation computation executed = NO
recommendation persistence = NO
sizing computation executed = NO
sizing persistence = NO
owner settings mutation = NO
provider calls = 0
Angel One calls = 0
Trendlyne calls = 0
OpenAI decision calls = 0
production mutation = NO
migration = NO
deployment = NO
merge = NO
scheduler change = NO
trading = NO
```

**Current stop boundary:** B3 candidate implemented; owner-local validation pending.
Do not begin B4.


### B3 Pharma dual-layer research invariant reinforcement

Owner clarified that Pharma is intentionally different from the ordinary sector
packages: each Pharma stock must be researched through both the common
`PHARMA_V1` research foundation and the reviewed Primary Pharma business-model
subprofile to which it belongs.

The canonical five Primary subprofiles remain:

```text
API_BULK_DRUGS
DOMESTIC_FORMULATIONS
GLOBAL_GENERICS
BIOPHARMA_BIOSIMILARS
CDMO_CRAMS
```

Repository audit confirmed the existing Pharma architecture already defines the
effective research contract as:

```text
PHARMA_V1 parent requirement
  + reviewed Primary subprofile override/addition
  + reviewed exposure condition
  + approved universal overlay requirement
  = effective security Pharma research contract
```

The five subprofiles remain children of `PHARMA_V1`; they do not replace the
parent profile.

B3 was tightened before owner-local validation in commit
`b9587227b09de6bc1a91092ac1a77516a642b315`:

- added a machine-readable
  `PROGRAM_B_PHARMA_DUAL_LAYER_RESEARCH` invariant;
- requires Pharma recommendation readiness to carry a canonical Primary subprofile;
- requires a Pharma subprofile assignment version;
- rejects a missing Primary as `BLOCKED_PREREQUISITE`;
- rejects a non-canonical Pharma Primary as `REVIEW_REQUIRED`;
- recommendation lineage now carries:
  - research parent profile code;
  - methodology role / Primary subprofile;
  - assignment version;
  in addition to the exact source score run and recommendation-policy identity;
- recommendation lineage identity changes when the Primary subprofile or assignment
  version changes;
- added regression cases proving
  `PHARMA_V1 + DOMESTIC_FORMULATIONS` cannot collapse into
  `PHARMA_V1 + GLOBAL_GENERICS`.

This does not create five top-level Pharma profiles and does not make five
independent stock scores. It preserves the established Pharma-specific layered
model: common Pharma research plus one Primary business-model research layer,
with secondary exposures/overlays handled only under separately approved rules.

No recommendation execution, sizing execution, provider call, persistence,
migration, deployment, merge, scheduler change or trading action occurred.

**B3 remains OPEN / OWNER-LOCAL VALIDATION PENDING.**


### B3 validation strengthening after Pharma dual-layer audit

After the owner-local B3 candidate runner reached `B3 CANDIDATE VALIDATION PASS`,
the validation surface was audited specifically for the Pharma architecture.

Confirmed repository behavior:
- Pharma remains a two-layer research model:
  - common `PHARMA_V1` parent research;
  - one reviewed Primary subprofile from the canonical five;
- the five canonical Primary subprofiles remain:
  - `API_BULK_DRUGS`;
  - `DOMESTIC_FORMULATIONS`;
  - `GLOBAL_GENERICS`;
  - `BIOPHARMA_BIOSIMILARS`;
  - `CDMO_CRAMS`;
- `composePharmaSubprofileContract(...)` composes the common parent exactly once
  and then applies the Primary subprofile additions/overrides;
- unresolved/provisional/disputed/conflicting Primary assignments remain
  fail-closed;
- Domestic-specific methodology cannot auto-apply to another Pharma Primary;
- secondary/material overlays do not create an independent second stock score;
- B3 recommendation readiness now requires the exact Pharma Primary and assignment
  version, and recommendation lineage retains parent profile + Primary + assignment
  version + exact source score run.

Validation-gap audit:
- the first B3 runner already tested the new Program B R7 dual-layer invariant and
  Gate I recommendation safety;
- however it did not explicitly re-run the older underlying Pharma assignment,
  effective-contract composition and subprofile-curve applicability regressions.

B3 validation was therefore strengthened in commit
`c5393dc631586a9ae42a79e4cc41dfbeb4ba6933` by adding:

- `src/features/research/pharmaSubprofileAssignment.test.ts`;
- `src/features/research/pharmaSubprofileContracts.test.ts`;
- `src/features/research/pharmaG6SubprofileCurveApplicability.test.ts`.

This is a test-runner strengthening only. No Pharma methodology, score,
recommendation, sizing, provider, database or production behavior was changed.

**B3 remains OPEN until the strengthened runner is re-executed locally.**
